Phase II Trial of Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Phase: PHASE2
Conditions: Hepatocellular Carcinoma
Sponsor: Abramson Cancer Center at Penn Medicine

Cover Page for ClinicalTrials.gov 
NCT Number 
NCT03781960 
Protocol 
Official Title 
PHASE II TRIAL OF ABEMACICLIB AND NIVOLUMAB FOR 
SUBJECTS WITH HEPATOCELLULAR CARCINOMA 
Documents 
Included 
study protocol and statistical analysis plan embedded within protocol section 
8.0 
Document 
Date 
(mm/dd/yyyy) 
12/14/2019 

  
 
 
 
PHASE II TRIAL OF ABEMACICLIB AND NIVOLUMAB FOR 
SUBJECTS WITH HEPATOCELLULAR CARCINOMA 
 
 
Principal Investigator 
Thomas Karasic 
Hematology/Oncology 
3400 Civic Center Blvd 10th Floor 
Philadelphia, PA 19104 
215-614-1858 
thomas.karasic@uphs.upenn.edu 
 
Sub-Investigators 
 
 
 
 
 
 
 
 
 
Collaborators 
 
 
 
 
Medical Monitor 
 
 
Statistician 
Kim Reiss-Binder 
Nevena Damjanov 
Charles Schneider 
Ursina Teitelbaum 
Mark O’Hara 
Jennifer Eads 
Ryan Massa 
 
Terence Gade 
Alexander Huang 
 
David Vaughn 
 
E. Paul Wileyto 
 
Investigational Product: 
 
Abemaciclib 
Protocol Number: 
IRB Number: 
Pending 
Pending 
IND/ IDE Number: 
 
N/A, IND Exempt 
 
 
 
ClinicalTrials.gov Number       
 
 
 
Pending 
 
 
Initial version 
09.27.18 
Revision #1 
10.19.18 
Revision #2 
11.13.18 
Revision #3 
12.07.18 
Revision #4        09.23.19 
 
 

Abemaciclib and Nivolumab for HCC 
Page ii 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
Table of Contents 
Contents 
LIST OF ABBREVIATIONS......................................................................................................................... IV 
STUDY SUMMARY ...................................................................................................................................... 1 
BACKGROUND AND STUDY RATIONALE ................................................................................................ 3 
1 
INTRODUCTION .................................................................................................................................. 3 
1.1 
BACKGROUND AND RELEVANT LITERATURE ..................................................................................... 3 
1.2 
NAME AND DESCRIPTION OF THE INVESTIGATIONAL PRODUCT .......................................................... 3 
1.2.1 
CLINICAL DATA TO DATE................................................................................................................. 3 
1.2.1.1 
HUMAN PHARMACOKINETICS ...................................................................................................... 3 
1.2.1.2 
CLINICAL STUDIES IN ADULTS ..................................................................................................... 6 
1.3 
NIVOLUMAB MECHANISM OF ACTION ............................................................................................... 7 
1.3.1 
NIVOLUMAB IN HEPATOCELLULAR CARCINOMA ................................................................................ 7 
1.4 
DOSE RATIONALE ........................................................................................................................... 7 
2 
STUDY OBJECTIVES ......................................................................................................................... 8 
2.1 
PRIMARY OBJECTIVE ...................................................................................................................... 8 
2.2 
SECONDARY OBJECTIVES ............................................................................................................... 8 
2.3 
EXPLORATORY OBJECTIVE ............................................................................................................. 8 
•
TO CORRELATE OUTCOMES WITH BLOOD AND TUMOR TISSUE IMMUNE MARKERS PRE- AND POST-THERAPY
TO EXPLORE POTENTIAL BIOMARKERS OF ANTI-TUMOR RESPONSE .................................................................. 8 
3 
INVESTIGATIONAL PLAN .................................................................................................................. 8 
3.1 
ABEMACICLIB DOSE AND SCHEDULE................................................................................................ 8 
3.1.1 
DOSE MODIFICATIONS FOR ABEMACICLIB ........................................................................................ 8 
3.1.2 
GENERAL GUIDANCE FOR INCREASES IN SERUM CREATININE AND ASSESSMENT OF RENAL 
INSUFFICIENCY WITH ABEMACICLIB ............................................................................................................. 12 
3.2 
NIVOLUMAB DOSE AND SCHEDULE ................................................................................................ 12 
3.3 
TREATMENT DURATION AND FOLLOW-UP ...................................................................................... 13 
3.4 
STUDY ENDPOINTS....................................................................................................................... 14 
3.4.1 
PRIMARY STUDY ENDPOINT .......................................................................................................... 14 
3.4.2 
SECONDARY STUDY ENDPOINTS ................................................................................................... 14 
4 
STUDY POPULATION ....................................................................................................................... 14 
4.1 
INCLUSION CRITERIA .................................................................................................................... 14 
4.2 
EXCLUSION CRITERIA ................................................................................................................... 15 
4.3 
SUBJECT RECRUITMENT ............................................................................................................... 16 
4.4 
TOTAL NUMBER OF SUBJECTS AND SITES...................................................................................... 16 
4.5 
VULNERABLE POPULATIONS ......................................................................................................... 16 
5 
STUDY INTERVENTION ................................................................................................................... 16 
5.1 
DESCRIPTION ............................................................................................................................... 16 
5.2 
INTERVENTION REGIMEN .............................................................................................................. 16 
5.3 
RECEIPT ...................................................................................................................................... 16 
5.4 
STORAGE .................................................................................................................................... 16 
5.5 
PREPARATION AND PACKAGING .................................................................................................... 16 
5.6 
ADMINISTRATION AND ACCOUNTABILITY ........................................................................................ 16 
5.7 
SUBJECT COMPLIANCE MONITORING ............................................................................................. 17 
6 
STUDY PROCEDURES ..................................................................................................................... 17 
6.1 
SCREENING (WITHIN 28 DAYS OF FIRST DOSE) .............................................................................. 19 

Abemaciclib and Nivolumab for HCC 
 
Page iii 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
6.2 
STUDY INTERVENTION PHASE ....................................................................................................... 19 
6.2.1 
CYCLE 1 ...................................................................................................................................... 19 
7 
STUDY EVALUATIONS AND MEASUREMENTS ............................................................................ 22 
7.1 
INFORMED CONSENT .................................................................................................................... 22 
7.2 
MEDICAL HISTORY AND DEMOGRAPHIC DATA ................................................................................ 22 
7.3 
PHYSICAL EXAMINATION ............................................................................................................... 22 
7.4 
VITAL SIGNS, HEIGHT, AND WEIGHT .............................................................................................. 22 
7.5 
ECOG PERFORMANCE STATUS .................................................................................................... 22 
7.6 
CONCOMITANT MEDICATIONS ....................................................................................................... 23 
7.7 
LABORATORY EVALUATIONS ......................................................................................................... 23 
7.8 
PREGNANCY TESTING .................................................................................................................. 24 
7.9 
INVESTIGATIONAL PRODUCT COMPLIANCE ..................................................................................... 24 
7.10 
DISEASE ASSESSMENTS ............................................................................................................... 24 
7.11 
CORRELATIVE STUDIES ................................................................................................................ 29 
7.11.1 
CORRELATIVE BLOOD SAMPLES ............................................................................................... 29 
7.11.2 
TUMOR BIOPSY........................................................................................................................ 29 
8 
STATISTICAL PLAN ......................................................................................................................... 30 
8.1 
PRIMARY ENDPOINT ..................................................................................................................... 30 
8.2 
SECONDARY ENDPOINTS .............................................................................................................. 30 
8.3 
SAMPLE SIZE AND POWER DETERMINATION ................................................................................... 30 
8.4 
STATISTICAL METHODS ................................................................................................................ 30 
8.4.4 
EXPLORATORY ENDPOINTS ........................................................................................................... 31 
9 
SAFETY AND ADVERSE EVENTS ................................................................................................... 31 
9.1 
DEFINITIONS ................................................................................................................................ 31 
9.1.1 
UNANTICIPATED PROBLEMS INVOLVING RISK TO SUBJECTS OR OTHERS .......................................... 31 
9.1.2 
ADVERSE EVENT .......................................................................................................................... 31 
9.1.3 
ADVERSE EVENTS OF SPECIAL INTEREST ...................................................................................... 31 
9.1.4 
SERIOUS ADVERSE EVENT ........................................................................................................... 31 
9.2 
ADVERSE EVENT REPORTING PERIOD ........................................................................................... 32 
9.2.1 
POST-STUDY ADVERSE EVENT ..................................................................................................... 33 
9.3 
RECORDING OF ADVERSE EVENTS ................................................................................................ 33 
9.4 
RELATIONSHIP OF AE TO STUDY ................................................................................................... 33 
9.5 
REPORTING OF ADVERSE EVENTS, ADVERSE DEVICE EFFECTS AND UNANTICIPATED PROBLEMS ..... 33 
9.5.1 
FOLLOW-UP REPORT .................................................................................................................... 33 
9.5.2 
INVESTIGATOR REPORTING: NOTIFYING DRUG MANUFACTURER (ELI LILLY) .................................... 34 
9.5.3 
INVESTIGATOR REPORTING: NOTIFYING THE PENN IRB .................................................................. 34 
9.5.4 
REPORTING PROCESS .................................................................................................................. 34 
9.5.5 
OTHER REPORTABLE EVENTS: ...................................................................................................... 34 
9.6 
ABRAMSON CANCER CENTER DATA SAFETY MONITORING COMMITTEE (DSMC): ............................ 35 
10 
STUDY ADMINISTRATION, DATA HANDLING AND RECORD KEEPING .................................... 37 
10.1 
CONFIDENTIALITY ......................................................................................................................... 37 
10.2 
DATA COLLECTION AND MANAGEMENT .......................................................................................... 37 
11 
STUDY MONITORING, AUDITING, AND INSPECTING .................................................................. 37 
11.1 
STUDY MONITORING PLAN ............................................................................................................ 37 
11.2 
AUDITING AND INSPECTING ........................................................................................................... 38 
12 
ETHICAL CONSIDERATIONS .......................................................................................................... 38 
13 
STUDY FINANCES ............................................................................................................................ 38 
13.1 
FUNDING SOURCE ........................................................................................................................ 38 
13.2 
CONFLICT OF INTEREST ................................................................................................................ 38 
14 
PUBLICATION PLAN ........................................................................................................................ 38 

Abemaciclib and Nivolumab for HCC 
 
Page iv 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
15 
REFERENCES .................................................................................................................................... 38 
 
 
 
 
 
List of Abbreviations 
 
 
AE 
Adverse event 
ALT 
Alanine aminotransferase  
ANC 
Absolute neutrophil count 
ALP 
Alkaline phosphatase 
AST 
Aspartate aminotransferase  
BUN 
Blood urea nitrogen 
CRF 
Case report form 
CT 
Computed tomography 
CTCAE 
(National Cancer Institute) Common Toxicity Criteria For Adverse Events 
CXR 
Chest X-Ray 
DNA 
Deoxyribonucleic acid 
DOR 
Duration of Response 
EKG 
Electrocardiogram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
Electronic Case Report Form 
GCP 
Good clinical practice 
HCC 
Hepatocellular carcinoma 
IB 
Investigator’s Brochure 
ICF 
Informed Consent Form 
IHC 
Immunohistochemistry 
IP 
Investigational Product 
IV 
Intravenous 
LFTs 
Liver function tests 
LLN 
Lower limit of normal 
MRI 
Magnetic Resonance Imaging 
ORR 
Overall Response Rate 
OS 
Overall Survival 
PD 
Progressive Disease 
PFS 
Progression-Free Survival 
PI 
Principal Investigator 
PR 
Partial Response 
PS 
Performance Status 
RNA 
Ribonucleic Acids 
SAE 
Serious adverse event 
SD 
Stable disease 
SUSAR 
Suspected unexpected serious adverse reaction 
TSH 
Thyroid Stimulating Hormone 
ULN 
Upper limit of normal  
WBC 
White blood cell count 
 
 
 
 
 
 

Abemaciclib and Nivolumab for HCC 
Page 1 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
Study Summary 
Title 
Phase II Trial of Abemaciclib and Nivolumab for Subjects with Hepatocellular 
Carcinoma 
Short Title 
Abemaciclib and Nivolumab for HCC 
IRB Number 
Pending 
Protocol Number 
Pending 
Phase 
Phase II 
Methodology 
Single-arm open-label 
Study Duration 
24 months (18 months for accrual and 6 additional months for follow-up) 
Study Center(s) 
University of Pennsylvania Abramson Cancer Center 
Objectives 
Primary: 
•
To determine the overall response rate
Secondary: 
•
To determine progression-free survival, duration of response, and
overall survival
•
To determine toxicity
Exploratory: 
•
To explore potential biomarkers of anti-tumor immunity in peripheral
blood and paired tissue biopsies
Number of Subjects 
27 evaluable 

Abemaciclib and Nivolumab for HCC 
 
Page 2 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
Main Inclusion and 
Exclusion Criteria 
1. Advanced HCC with histologic confirmation 
2. Retinoblastoma (RB) positive by immunohistochemistry 
3. ECOG PS 0 or 1 
4. Childs-Pugh A or B7 
5. ANC > 1500 x 109/L 
6. Platelets > 75,000 x 109/L 
7. No prior therapy with a PD-1, PD-L1, or CDK4/6 inhibitor 
8. No uncontrolled ascites 
9. No esophageal varices requiring treatment in the past 6 months 
10. No serious autoimmune disease, interstitial lung disease, or solid 
organ transplant 
11. No use of systemic corticosteroids other than for adrenal hormone 
replacement   
Investigational 
Product 
 
Abemaciclib 150mg by mouth twice daily 
 
Duration of 
administration 
Until progression, intolerance, or withdrawal of consent 
Reference therapy 
Historic results from nivolumab in HCC 
Statistical 
Methodology 
Primary endpoint will be overall response rate (ORR) by RECIST v. 1.1.  This 
will be compared to historical ORR with nivolumab.  Toxicity rates will be 
calculated using CTCAE v. 5.0.  Kaplan-Meier methods will be used to 
calculate PFS, DOR, and OS using RECIST v. 1.1 and iRECIST criteria 
 
With 27 subjects, a one-sided binomial test with alpha = 0.10 will have 81% 
power to detect an improvement in ORR from 18% (H0) to 36% (H1). 
 
 
 

Abemaciclib and Nivolumab for HCC 
 
Page 3 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
BACKGROUND AND STUDY RATIONALE 
This study will be conducted in full accordance all applicable University of Pennsylvania Research Policies 
and Procedures and all applicable Federal and state laws and regulations. 
1 
Introduction  
Hepatocellular carcinoma is the second leading cause of cancer deaths worldwide, resulting in an estimated 
810,000 deaths in 2015 [1].  Even as deaths from other common cancers have declined in the United 
States, mortality from HCC has doubled in the past two decades, and HCC is now the fifth-leading cause 
of cancer deaths in the U.S. [2].  For patients with advanced HCC not amenable to ablation, surgical 
resection, or transplant, median survival is less than one year.  The accelerated approval of the PD-1 
inhibitor nivolumab by the FDA in 2017 illustrates the benefit of immunotherapy for advanced HCC, but, 
with an overall response rate (ORR) of only 15-20% in studies of pembrolizumab and nivolumab in HCC, 
more effective combinations are clearly needed [3, 4]. 
1.1 
Background and Relevant Literature  
 
Recent preclinical studies have demonstrated potentiation of anti-tumor immunity and increases in tumor-
infiltrating lymphocytes by CDK4/6 inhibitors as well as synergy between PD-1 and CDK4/6 inhibitors [5-8].  
Mechanisms demonstrated have included inhibition of proliferation of regulatory T cells (Treg), enhanced 
antigen presentation and type III interferon production, decreased PD-L1 degradation, decreases in 
myeloid-derived suppressor cells (MDSCs), and increased IL-2 production due to derepression of nuclear 
factor of activated T cells (NFAT) pathways.  Improvement in response has been shown with an initial 7-
day run-in of abemaciclib prior to PD-L1 therapy compared to concurrent or sequential administration [9].  
Additionally, single agent activity of CDK4/6 inhibitors has been demonstrated in RB-positive HCC, which 
account for about 70% of tumors, with impaired tumor growth and improved survival in murine models [10].   
A single-arm phase II trial of palbociclib showed a median progression-free survival of nearly 6 months, but 
the clinical efficacy of CDK4/6 inhibitors has never been further explored in a randomized study in HCC 
[11].  As a single agent in HCC, nivolumab has demonstrated an overall response rate of 15-20% [3] and 
received accelerated approval from the FDA in HCC based on the results of the Checkmate-040. 
 
We hypothesize that the addition of abemaciclib to nivolumab in advanced HCC will double the 
overall response rate (ORR) compared to nivolumab alone by both enhancing anti-tumor immunity 
and inhibiting cell cycle progression. 
 
Ongoing studies in breast cancer and non-small cell lung cancer have demonstrated the safety of 
abemaciclib and pembrolizumab at standard doses, and it is assumed that the combination of abemaciclib 
and nivolumab will be similarly tolerable in an HCC population [12].  This will be a single-arm phase II trial 
to test the initial efficacy of this combination and elucidate the immune effects of abemaciclib in HCC. 
1.2 
Name and Description of the Investigational Product  
Abemaciclib is an oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6).  These kinases are 
activated upon binding to D-cyclins.  Cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma 
protein (Rb), cell cycle progression, and cell proliferation.  In vitro, continuous exposure to abemaciclib 
inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in 
senescence and apoptosis. 
1.2.1 
Clinical Data to Date 
1.2.1.1 
Human Pharmacokinetics 
The pharmacokinetics of abemaciclib were characterized in patients with solid tumors, including metastatic 
breast cancer, and in healthy subjects. Following single and repeated twice daily dosing of 50 mg (0.3 times 
the approved recommended 150 mg dosage) to 200 mg of abemaciclib, the increase in plasma exposure 
(AUC) and Cmax was approximately dose proportional. Steady state was achieved within 5 days following 

Abemaciclib and Nivolumab for HCC 
Page 4 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
repeated twice daily dosing, and the estimated geometric mean accumulation ratio was 2.3 (50% CV) and 
3.2 (59% CV) based on Cmax and AUC, respectively.  
Absorption  
The absolute bioavailability of abemaciclib after a single oral dose of 200 mg is 45% (19% CV). The median 
Tmax of abemaciclib is 8.0 hours (range: 4.1-24.0 hours).  
Effect of Food 
A high-fat, high-calorie meal (approximately 800 to 1000 calories with 150 calories from protein, 250 
calories from carbohydrate, and 500 to 600 calories from fat) administered to healthy subjects increased 
the AUC of abemaciclib plus its active metabolites by 9% and increased Cmax by 26%.  
Distribution 
In vitro, abemaciclib was bound to human plasma proteins, serum albumin, and alpha-1-acid glycoprotein 
in a concentration independent manner from 152 ng/mL to 5066 ng/mL. In a clinical study, the mean 
(standard deviation, SD) bound fraction was 96.3% (1.1) for abemaciclib, 93.4% (1.3) for M2, 96.8% (0.8) 
for M18, and 97.8% (0.6) for M20. The geometric mean systemic volume of distribution is approximately 
690.3 L (49% CV). In patients with advanced cancer, including breast cancer, concentrations of abemaciclib 
and its active metabolites M2 and M20 in cerebrospinal fluid are comparable to unbound plasma 
concentrations. 
Elimination  
The geometric mean hepatic clearance (CL) of abemaciclib in patients was 26.0 L/h (51% CV), and the 
mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV).  
Metabolism: Hepatic metabolism is the main route of clearance for abemaciclib. Abemaciclib is metabolized 
to several metabolites primarily by cytochrome P450 (CYP) 3A4, with formation of N-desethylabemaciclib 
(M2) representing the major metabolism pathway. Additional metabolites include hydroxyabemaciclib 
(M20), hydroxy-N-desethylabemaciclib (M18), and an oxidative metabolite (M1). M2, M18, and M20 are 
equipotent to abemaciclib and their AUCs accounted for 25%, 13%, and 26% of the total circulating analytes 
in plasma, respectively.  
Excretion: After a single 150 mg oral dose of radiolabeled abemaciclib, approximately 81% of the dose was 
recovered in feces and approximately 3% recovered in urine. The majority of the dose eliminated in feces 
was metabolites.  
Specific Populations 
Age, Gender, and Body Weight Based on a population pharmacokinetic analysis in patients with cancer, 
age (range 24-91 years), gender (134 males and 856 females), and body weight (range 36-175 kg) had no 
effect on the exposure of abemaciclib.  
Patients with Renal Impairment: In a population pharmacokinetic analysis of 990 individuals, in which 381 
individuals had mild renal impairment (60 mL/min ≤ CLcr <90 mL/min) and 126 individuals had moderate 
renal impairment (30 mL/min ≤ CLcr <60 mL/min), mild and moderate renal impairment had no effect on 
the exposure of abemaciclib.  The effect of severe renal impairment (CLcr <30 mL/min) on 
pharmacokinetics of abemaciclib is unknown.  
Patients with Hepatic Impairment: Following a single 200 mg oral dose of abemaciclib, the relative potency 
adjusted unbound AUC 0-INF of abemaciclib plus its active metabolites (M2, M18, M20) in plasma 
increased 1.2-fold in subjects with mild hepatic impairment (Child-Pugh A, n=9), 1.1-fold in subjects with 
moderate hepatic impairment (Child-Pugh B, n=10), and 2.4-fold in subjects with severe  
hepatic impairment (Child-Pugh C, n=6) relative to subjects with normal hepatic function (n=10). In subjects 
with severe hepatic impairment, the mean plasma elimination half-life of abemaciclib increased to 55 hours 
compared to 24 hours in subjects with normal hepatic function.  

Abemaciclib and Nivolumab for HCC 
Page 5 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
Drug Interaction Studies  
Effects of Other Drugs on Abemaciclib 
Strong CYP3A Inhibitors:  
•
Ketoconazole (a strong CYP3A inhibitor) is predicted to increase the AUC of abemaciclib by up to
16-fold.
•
Itraconazole (a strong CYP3A inhibitor) is predicted to increase the relative potency adjusted
unbound AUC of abemaciclib plus its active metabolites (M2, M18 and M20) by 2.2-fold.
•
Coadministration of 500 mg twice daily doses of clarithromycin (a strong CYP3A inhibitor) with a
single 50 mg dose of abemaciclib (0.3 times the approved recommended 150 mg dosage)
increased the relative potency adjusted unbound AUC 0-INF of abemaciclib plus its active
metabolites (M2, M18, and M20) by 1.7-fold relative to abemaciclib alone in cancer patients.
Moderate CYP3A Inhibitors: 
•
Diltiazem and verapamil (moderate CYP3A inhibitors) are predicted to increase the relative potency
adjusted unbound AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by 1.7-fold
and 1.3-fold, respectively.
Strong CYP3A Inducers: 
•
Coadministration of 600 mg daily doses of rifampin (a strong CYP3A inducer) with a single 200 mg
dose of VERZENIO decreased the relative potency adjusted unbound AUC0-INF of abemaciclib
plus its active metabolites (M2, M18, and M20) by 67% in healthy subjects.
Moderate CYP3A Inducers: 
•
The effect of moderate CYP3A inducers on the pharmacokinetics of abemaciclib is unknown.
Loperamide: 
•
Co-administration of a single 8-mg dose of loperamide with a single 400-mg dose of abemaciclib
in healthy subjects increased the relative potency adjusted unbound AUC0-INF of abemaciclib plus
its active metabolites (M2 and M20) by 12%, which is not considered clinically relevant.
Fulvestrant: 
•
In clinical studies in patients with breast cancer, fulvestrant had no clinically relevant effect on the
pharmacokinetics of abemaciclib or its active metabolites.
• 
 
Effects of Abemaciclib on Other Drugs 
Loperamide: 
•
In a clinical drug interaction study in healthy subjects, coadministration of a single 8 mg dose of
loperamide with a single 400 mg abemaciclib (2.7 times the approved recommended 150 mg
dosage) increased loperamide AUC0-INF by 9% and Cmax by 35% relative to loperamide alone.
These increases in loperamide exposure are not considered clinically relevant.
Metformin: 
•
In a clinical drug interaction study in healthy subjects, coadministration of a single 1000 mg dose
of metformin, a clinically relevant substrate of renal OCT2, MATE1, and MATE2-K transporters,
with a single 400 mg dose of abemaciclib (2.7 times the approved recommended 150 mg dosage)
increased metformin AUC0-INF by 37% and Cmax by 22% relative to metformin alone. Abemaciclib
reduced the renal clearance and renal secretion of metformin by 45% and 62%, respectively,
relative to metformin alone, without any effect on glomerular filtration rate (GFR) as measured by
iohexol clearance and serum cystatin C.
Fulvestrant: 
•
In clinical studies in patients with breast cancer, abemaciclib had no clinically relevant effect on
fulvestrant pharmacokinetics.
In Vitro Studies 

Abemaciclib and Nivolumab for HCC 
Page 6 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
Transporter Systems: 
Abemaciclib and its major active metabolites inhibit the renal transporters OCT2, MATE1, and MATE2-K 
at concentrations achievable at the approved recommended dosage. The observed serum creatinine 
increase in clinical studies with abemaciclib is likely due to inhibition of tubular secretion of creatinine via 
OCT2, MATE1, and MATE2-K. Abemaciclib and its major metabolites at clinically relevant concentrations 
do not inhibit the hepatic uptake transporters OCT1, OATP1B1, and OATP1B3 or the renal uptake 
transporters OAT1 and OAT3.  
Abemaciclib is a substrate of P-gp and BCRP. Abemaciclib and its major active metabolites, M2 and M20, 
are not substrates of hepatic uptake transporters OCT1, organic anion transporting polypeptide 1B1 
(OATP1B1), or OATP1B3.  
Abemaciclib inhibits P-gp and BCRP. The clinical consequences of this finding on sensitive P-gp and 
BCRP substrates are unknown. 
CYP Metabolic Pathways: 
Abemaciclib and its major active metabolites, M2 and M20, do not induce CYP1A2, CYP2B6, or CYP3A 
at clinically relevant concentrations. Abemaciclib and its major active metabolites, M2 and M20, 
downregulate mRNA of CYPs, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6 and CYP3A4. 
The mechanism of this down regulation and its clinical relevance are not understood. However, 
abemaciclib is a substrate of CYP3A4, and time-dependent changes in pharmacokinetics of abemaciclib 
as a result of autoinhibition of its metabolism was not observed. 
P-gp and BCRP Inhibitors:
In vitro, abemaciclib is a substrate of P-gp and BCRP. The effect of P-gp or BCRP inhibitors on the
pharmacokinetics of abemaciclib has not been studied.
1.2.1.2 
Clinical Studies in Adults 
MONARCH 1 (NCT02102490) was a single-arm, open-label, multicenter study in women with measurable 
HR-positive, HER2-negative metastatic breast cancer whose disease progressed during or after 
endocrine therapy, had received a taxane in any setting, and who received 1 or 2 prior chemotherapy 
regimens in the metastatic setting [13].  A total of 132 patients received 200 mg abemaciclib orally twice 
daily on a continuous schedule until development of progressive disease or unmanageable toxicity.  The 
median duration of treatment was 4.5 months.  The most common grade 3/4 toxicities with abemaciclib 
were diarrhea (20% Grade 3), neutropenia (19% Grade 3, 5%  Grade 4), nausea (5% Grade 3), infections 
(5% Grade 3, 2% Grade 4), fatigue (13% Grade 3), anemia (5% Grade 3), thrombocytopenia (4% Grade 
3), and decreased appetite (3% Grade 3). 
MONARCH 2 (NCT02107703) was a randomized, placebo-controlled, multicenter study in women with 
HR-positive, HER2-negative metastatic breast cancer in combination with fulvestrant in patients with 
disease progression following endocrine therapy who had not received chemotherapy in the metastatic 
setting [14]. A total of 669 patients were randomized to receive abemaciclib or placebo orally twice daily 
plus intramuscular injection of 500 mg fulvestrant on days 1 and 15 of cycle 1 and then on day 1  
of cycle 2 and beyond (28-day cycles). Patients remained on continuous treatment until development of 
progressive disease or unmanageable toxicity. MONARCH 2 met its primary endpoint with an 
improvement in PFS (median 16.4 vs. 9.3 months, HR 0.553, p<0.0001).  The most common grade 3/4 
toxicities with abemaciclib in MONARCH 2 were neutropenia (24% Grade 3, 3% Grade 4) and diarrhea 
(13% Grade 3). anemia (7% Grade 3, <1% Grade 4), thrombocytopenia (2% Grade 3, 1% Grade 4), 
infections (5% Grade 3, <1% Grade 4), nausea (3% Grade 3), ALT increase (4% Grade 3, <1% Grade 4) 
and fatigue (3% Grade 3).  Further details about MONARCH 1 and MONARCH 2 are available in the FDA 
package insert for abemaciclib. 

Abemaciclib and Nivolumab for HCC 
Page 7 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
1.3 
Nivolumab Mechanism of Action 
PD-1 is a member of the CD28 family of T-cell co-stimulatory receptors that also includes CD28, CTLA 4, 
ICOS, and BTLA.  PD-1 signaling has been shown to inhibit CD-28-mediated upregulation of IL-2, IL-10, 
IL-13, interferon-γ (IFN-γ) and Bcl-xL. PD-1 expression also been noted to inhibit T cell activation, and 
expansion of previously activated cells. Evidence for a negative regulatory role of PD-1 comes from studies 
of PD-1 deficient mice, which develop a variety of autoimmune phenotypes.  These results suggest that 
PD-1 blockade has the potential to activate anti-self T-cell responses, but these responses are variable and 
dependent upon various host genetic factors. Thus, PD-1 deficiency or inhibition is not accompanied by a 
universal loss of tolerance to self-antigens. 
In vitro, nivolumab (BMS-936558) binds to PD-1 with high affinity (EC50 0.39-2.62 nM), and inhibits the 
binding of PD-1 to its ligands PD-L1 and PD-L2 (IC50 + 1 nM). Nivolumab binds specifically to PD-1 and 
not to related members of the CD28 family such as CD28, ICOS, CTLA-4 and BTLA. Blockade of the PD-
1 pathway by nivolumab results in a reproducible enhancement of both proliferation and IFN-γ release in 
the mixed lymphocyte reaction (MLR). In vivo blockade of PD-1 by a murine analog of nivolumab enhances 
the anti-tumor immune response and result in tumor rejection in several immunocompetent mouse tumor 
models (MC38, SA1/N, and PAN02).  Clinical efficacy has been demonstrated in a variety of tumor types, 
and it is currently FDA approved for the treatment of melanoma, non-small cell lung cancer, Hodgkin’s 
lymphoma, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, 
microsatellite instability-high tumors, and hepatocellular carcinoma 
1.3.1 
Nivolumab In Hepatocellular Carcinoma 
Nivolumab was initially tested in hepatocellular carcinoma in the phase I/II Checkmate-040 study [3].  This 
was an open-label, non-comparative dose escalation and expansion trial.  A total of 262 subjects were 
treated in the two phases of the study.  In the dose-escalation portion, the overall response rate was 15%, 
with a disease control rate of 58% and a median overall survival of 15.0 months.  In the dose expansion 
phase, an objective response rate of 20% was demonstrated, and median survival was not reached in the 
overall population.  Response rates were similar regardless of viral hepatitis status or prior treatment with 
sorafenib.  Toxicity was manageable, with 25% grade 3/4 adverse events, most commonly rash (23%), 
AST increase (21%), ALT increase (15%), lipase increase (21%), amylase increase (19%), and pruritis 
(19%).  Treatment-related serious adverse events were seen in 6% of patients in the dose-escalation of 
cohort.  Only 20% of subjects had PD-L1 expression of > 1% by IHC, and this did not correlate with response 
rate.  Based on the results of this study, nivolumab received accelerated approval from the FDA for HCC. 
A phase III trial (Checkmate-459) comparing sorafenib to nivolumab for the initial treatment of advanced 
HCC is ongoing. 
1.4 
Dose Rationale 
A phase 1b study of abemaciclib 150mg twice daily with the PD-1 inhibitor pembrolizumab 200mg every 3 
weeks in women with breast cancer demonstrated tolerability, with no additional toxicity expected from 
either therapy as  single agents [12].  The toxicities of pembrolizumab and nivolumab are expected to be 
similar in this study population and thus abemaciclib 150mg twice daily is expected to be similarly tolerable. 
The initial 7-day run-in of abemaciclib prior to starting nivolumab is based on preclinical data showing 
enhanced synergy compared to concurrent or sequential dosing [9]. 
The Checkmate-040 study which led to the accelerated approval of nivolumab in HCC used a dose of 
240mg every 2 weeks.  More recently, the FDA label for nivolumab has added the option of 480mg every 
4 weeks for most nivolumab indications, including in hepatocellular carcinoma.  The nivolumab doses of 
480 mg Q4W was selected for this study based on clinical pharmacokinetic data and modeling showing 
similar drug exposure and no change in safety compared to dosing every 2 weeks using either weight-
based (3mg/kg) or flat dose (240mg) regimens. 

Abemaciclib and Nivolumab for HCC 
Page 8 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
2 
Study Objectives 
2.1 
Primary Objective 
•
To determine ORR of abemaciclib plus nivolumab in HCC as measured by RECIST v. 1.1
2.2 
Secondary Objectives 
•
To determine PFS and DOR of abemaciclib plus nivolumab in HCCas measured by both RECIST
v 1.1 and iRECIST.  To measure ORR by iRECIST.  To summarize OS using Kaplan-Meier
methods
•
To determine toxicity rates by category using CTCAE v. 5.0
2.3 
Exploratory Objective 
•
To correlate outcomes with blood and tumor tissue immune markers pre- and post-therapy to
explore potential biomarkers of anti-tumor response
3 
Investigational Plan 
Subjects with advanced hepatocellular carcinoma will be enrolled in this single-arm open-label phase II 
study.  Subjects will receive abemaciclib monotherapy 150mg twice daily for seven days then will initiate 
nivolumab 480mg IV every 28 days while continuing twice daily abemaciclib.  Subjects will continue therapy 
until progression of disease, unacceptable toxicity, or withdrawal of consent. 
Figure 1: Treatment Schema 
3.1 
Abemaciclib Dose and Schedule 
Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial 
therapy. 
3.1.1 
Dose Modifications for Abemaciclib 
If a subject experiences any of the following toxicities (grading per CTCAE v. 5.0) that are considered at 
least possible related to abemaciclib, abemaciclib will be modified as follows: 
Table 1: Dose Levels for Abemaciclib 
Dose Level 
Dose of abemaciclib 
0 
150mg twice daily 
-1
100mg twice daily 
-2
50mg twice daily 
If further dose-reduction beyond 50mg 
twice daily is required, discontinue 
abemaciclib permanently 
Hematologic toxicities 
•
Grade 1 or 2: No abemaciclib dosage adjustment necessary

Abemaciclib and Nivolumab for HCC 
 
Page 9 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
• Grade 3: Withhold abemaciclib until toxicity resolves to < Grade 2; no dose reduction of 
abemaciclib is necessary 
• Grade 4 or recurrent Grade 3: Withhold abemaciclib until toxicity resolves to < Grade 2 and then 
resume abemaciclib at the next lower dose (see Table 1) 
 
If blood cell growth factors (e.g. filgrastim) are administered, hold abemaciclib for at least 48 hours after the 
last dose of blood cell growth factor and until toxicity resolves to < grade 2.  Resume at next lower dose 
(see Table 1) unless already performed for the toxicity that led to the use of the growth factor.   
 
Non-hematologic toxicities: 
• Diarrhea: At the first sign of loose stools, begin management with antidiarrheal agents and 
increase oral fluid intake.  Response should be assessed within 24 hours. 
o 
Grade 1: No abemaciclib dosage adjustment necessary 
o 
Grade 2: If toxicity does not resolve to < Grade 1 within 24 hours, withhold abemaciclib 
until resolution (no abemaciclib dosage reduction is necessary) 
o 
Grade 2 that persists or recurs after resumption at the same dose (despite maximal 
supportive measures): Withhold abemaciclib until toxicity resolves to < Grade 1 and 
then resume abemaciclib at the next lower dose (see Table 1) 
o 
Grade 3 or 4 or requires hospitalization: Withhold abemaciclib until toxicity resolves to 
< Grade 1 and then resume abemaciclib at the next lower dose (see Table 1) 
• 
Hepatotoxicity: 
Table 2: Dose Modifications and Management Of Abemaciclib For Hepatotoxicity 
Monitor ALT prior to the start of abemaciclib therapy, every 2 weeks for the first 2 months, 
monthly for the next 2 months, and as clinically indicated. 
CTCAE Grade 
Abemaciclib Dose Modifications 
Grade 1 (>ULN-3.0 x ULN) 
Grade 2 (>3.0-5.0 x ULN) 
No dose modification is required. 
Persistent or Recurrent Grade 2, 
or Grade 3 (>5.0-20.0 x ULN) 
that does not resolve with 
maximal supportive measures 
within 7 days to baseline or Grade 
1 
Suspend dose until toxicity resolves to baseline or Grade 
1. 
Resume at next lower dose. 
Grade 3 (˃5.0 x ULN)  
with total bilirubin >2 x ULN, in 
the absence of cholestasis 
Discontinue abemaciclib. 
Grade 4 (>20.0 x ULN) 
Discontinue abemaciclib. 
 
To ensure patient safety the investigator should collect specific recommended clinical information 
and follow-up laboratory tests as shown below in Table 3.  
 
Details for hepatic monitoring depend upon the severity and persistence of observed laboratory test 
abnormalities. If a study patient experiences elevated ALT 5×ULN and elevated TBL 2×ULN, or ALT 
8×ULN, liver tests, including ALT, AST, TBL, direct bilirubin, gamma-glutamyl transferase (GGT), and 
creatine phosphokinase (CPK), should be repeated within 3 to 5 days to confirm the abnormality and to 

Abemaciclib and Nivolumab for HCC 
Page 10 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
determine if it is increasing or decreasing.  If the abnormality persists or worsens, clinical and laboratory 
monitoring should be initiated by the investigator, based on the hepatic monitoring tests below.  
In the event that hepatotoxicity requiring discontinuation of abemacicilib is observed, a complete laboratory 
evaluation as detailed in Table 3 should be performed. 
Table 3: Hepatic Monitoring Tests for a Hepatic Treatment Emergent Abnormality. 
Hepatic Hematology 
Haptoglobin 
Hemoglobin 
Hematocrit 
Hepatic Coagulation 
RBC 
Prothrombin Time 
WBC 
Prothrombin Time, INR 
Neutrophils, segmented and bands 
Lymphocytes 
Hepatic Serologiesa 
Monocytes 
Hepatitis A antibody, total 
Eosinophils 
Hepatitis A antibody, IgM 
Basophils 
Hepatitis B surface antigen 
Platelets 
Hepatitis B surface antibody 
Hepatitis B Core antibody 
Hepatic Chemistry 
Hepatitis C antibody 
Total bilirubin 
Hepatitis E antibody, IgG 
Direct bilirubin 
Hepatitis E antibody, IgM 
Alkaline phosphatase 
ALT 
Anti-nuclear antibody 
AST 
Anti-actin antibody 
GGT 
CPK  
Anti-smooth muscle antibody 
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma-glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cells; WBC = white blood cells. 
a Reflex/confirmation dependent on regulatory requirements and/or testing availability. 
Table 4: Dose Modification and Management — Hematologic Toxicities 
Monitor complete blood counts prior to the start of abemaciclib therapy, every 2 weeks for the first 2 
months, monthly for the next 2 months, and as clinically indicated. 
CTCAE Grade 
Abemaciclib Dose Modifications 
Grade 1 or 2 
No dose modification is required. 
Grade 3 
Suspend dose until toxicity resolves to ≤Grade 2. 
Dose reduction is not required. 
Grade 3, recurrent, or Grade 4 
Suspend dose until toxicity resolves to ≤Grade 2. 
Resume at next lower dose. 
Patient requires administration of 
a blood cell growth factor 
Suspend abemaciclib dose for at least 48 hours after the last 
dose of blood cell growth factor and until toxicity resolves to 
≤Grade 2. 

Abemaciclib and Nivolumab for HCC 
Page 11 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
Resume abemaciclib at next lower dose unless the dose was 
already reduced for the toxicity that led to the use of the 
growth factor. 
General Guidance for Interstitial lung disease (ILD)/Pneumonitis events 
Interstitial lung disease (ILD) / pneumonitis has been identified as an adverse drug reaction for 
abemaciclib. Adverse events reported included events such as interstitial lung disease, pneumonitis, 
obliterative bronchiolitis, organizing pneumonia, pulmonary fibrosis. The majority of events were Grade 1 
or Grade 2 with serious cases and fatal events reported.  
Monitor for clinical symptoms or radiological changes indicative of ILD/pneumonitis and please ask 
patients to report any new or worsening pulmonary symptoms. Symptoms may include hypoxia, cough, 
dyspnea, or interstitial infliltrates on radiologic exams.; these symptoms should be investigated and 
treated as per local clinical practice and/or guidelines (including corticosteroids as appropriate). 
Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate 
investigations. Investigations may include imaging such as high resolution computer tomography (HRCT), 
broncheoalveolar lavage (BAL), and biopsy as clinically indicated (see also Table 7: refer to dose 
adjustment table for interstitial lung disease/pneumonitis).  
Table 5: Dose Modification and Management — Interstitial Lung Disease/Pneumonitis 
CTCAE Grade 
Abemaciclib Dose Modifications 
Grade 1 or 2 
No dose modification is required. 
Persistent or recurrent Grade 2 
toxicity that does not resolve with 
maximal supportive measures 
within 7 days to baseline or Grade 
1 
Suspend dose until toxicity resolves to baseline or Grade 1. 
Resume at next lower dose. 
Grade 3 or 4 
Discontinue abemaciclib. 
Table 6: Dose Modification and Management — Nonhematologic Toxicities Excluding Diarrhea, 
ALT Increased, and ILD/Pneumonitis 
CTCAE Grade 
Abemaciclib Dose Modifications 
Grade 1 or 2 
No dose modification is required. 
Persistent or recurrent Grade 2 
toxicity that does not resolve with 
maximal supportive measures 
within 7 days to baseline or Grade 
1 
Suspend dose until toxicity resolves to baseline or Grade 1. 
Resume at next lower dose. 
Grade 3 or 4 
•
Other toxicities attributable to abemaciclib:
o
Grade 1 or 2: No dose modification is required
o
Persistent or recurrent Grade 2 toxicity that does not resolve with maximal supportive
measures within 7 days to baseline or Grade 1: Withhold abemaciclib until toxicity resolves
to baseline or < Grade 1.  Resume at next lower dose (see Table 1).

Abemaciclib and Nivolumab for HCC 
 
Page 12 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
o 
Grade 3 or 4: Withhold abemaciclib until toxicity resolves to baseline or < Grade 1.  Resume 
at next lower dose (see Table 1). 
For any toxicity of abemaciclib (regardless of grade) that, despite optimal supportive care, is felt by the 
treating Investigator to present a risk to safety of the study subject, additional dose reduction, treatment 
delay, or treatment discontinuation is permitted at the discretion of the treating Investigator.  Subjects in 
whom abemaciclib is held or discontinued may continue to receive nivolumab and remain on study. 
3.1.2 
General Guidance for Increases in Serum Creatinine and Assessment of Renal Insufficiency 
with Abemaciclib 
Elevation of serum creatinine is observed with abemaciclib and is due to a pharmacological inhibitory effect 
of abemaciclib on renal tubular transporters without affecting glomerular function. The rise in serum 
creatinine (mean increase, 0.2 mg/dL) occurs within the first 28-day cycle of abemaciclib, and remains 
elevated but stable throughout the treatment period, and is reversible upon treatment discontinuation. 
Alternative markers (such as BUN, cystatin C level, or cystatin C calculated GFR ) which are not based on 
creatinine, may be considered to determine whether renal function is impaired. 
3.2 
Nivolumab Dose and Schedule 
Nivolumab will be administered at a dose of 480mg IV every 28 days.  Treatment with nivolumab will begin 
after an initial 7-day treatment period with abemaciclib monotherapy (see Figure 1: Treatment Schema).  
No dose modifications of nivolumab are permitted.  Subjects who experience toxicity related to nivolumab 
will be managed in accordance with guidelines in the management algorithms provided in the nivolumab 
package label, with modifications relevant to the treatment population 
 
Table 4:  Dose Modifications and Delays For Nivolumab Toxicity 
Adverse Reaction 
Severity 
Dose Modificaiton 
Colitis 
Grade 2 diarrhea or colitis 
Withhold dose 
 
Grade 3 diarrhea or colitis 
Withhold dose 
 
Grade 4 diarrhea or colitis 
Permanently discontinue 
Pneumonitis 
Grade 2 pneumonitis 
Withhold dose 
 
Grade 3 pneumonitis 
Permanently discontinue 
Hepatitis 
• 
If AST/ALT is within normal 
limits 
at 
baseline 
and 
increases to more than 3 and 
up to 5 times the ULN 
• 
If AST/ALT is more than 1 
and up to 3 times ULN at 
baseline and increases to 
more than 5 and up to 20 
times the ULN 
Withhold dose 
 
If AST or ALT increases to more 
than 20 times the ULN or total 
bilirubin increases to more than 3 
times the ULN 
Permanently discontinue 
Hypophysitis 
Grade 2 or 3 hypophysitis 
Withhold dose 
Grade 4 hypophysitis 
Permanently discontinue 
Adrenal Insufficiency 
Grade 2 
Withhold dose 
 
Grade 3 or 4 
Permanently discontinue 
Type 1 Diabetes Mellitus 
Grade 3 hyperglycemia 
Withhold dose 

Abemaciclib and Nivolumab for HCC 
Page 13 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
Grade 4 hyperglycemia 
Permanently discontinue 
Nephritis 
Serum creatinine more than 1.5 
and up to 6 times the ULN 
Withhold dose 
Serum creatinine more than 6 
times the ULN 
Permanently discontinue 
Skin 
Grade 3 rash or suspected 
Stevens-Johnson 
syndrome 
(SJS) 
or 
toxic 
epidermal 
necrolysis (TEN) 
Withhold dose 
Grade 4 rash or confirmed SJS 
or TEN 
Permanently discontinue 
Encephalitis 
New-onset moderate or severe 
neurologic signs or symptoms 
Withhold dose 
Immune-mediated encephalitis 
Permanently discontinue 
Other 
Other Grade 3 Adverse Reaction 
(except for amylase or lipase 
elevations in absence of clinical 
pancreatitis) 
•
Withhold dose for first
occurrence
•
Permanently discontinue for
recurrence of same Grade 3
adverse event
Life-threatening 
or 
Grade 
4 
adverse reaction 
Permanently discontinue 
Grade 3 myocarditis 
Permanently discontinue 
Requirement for 10mg per day or 
greater 
of 
prednisone 
or 
equivalent for more than 12 
weeks 
Permanently discontinue 
Persistent grade 2 or 3 adverse 
reactions lasting 12 weeks or 
longer 
Permanently discontinue 
These dose adjustments are for AEs deemed related to nivolumab using CTCAE v. 5.0.  If in the opinion of 
the treating Investigator, a toxicity is thought to be unrelated to nivolumab, no dose delay for nivolumab is 
necessary.  If treatment is withheld per the above table, it should be held until the toxicity has returned to 
Grade < 1. 
Subjects with drug-related endocrinopathies controlled with hormone replacement such as insulin or 
adrenal replacement-dose steroids may resume treatment when toxicity has improved to Grade < 1.  Dose 
interruption is not required for hyper- or hypothyroidism but supportive care (e.g. thyroid replacement) 
should be started per institutional standards. 
Corticosteroids are frequently indicated for Grade 3 or greater toxicities, and are necessary at times for 
lower grade toxicities.  Guidance for their use and dosing is available in nivolumab package label.  For any 
toxicity of nivolumab (regardless of grade) that, despite optimal supportive care, is felt by the treating 
Investigator to present a risk to safety of the study subject, additional treatment delay or treatment 
discontinuation is permitted at the discretion of the treating Investigator. 
3.3 
Treatment Duration and Follow-Up 
Subjects will remain on study therapy until disease progression, unacceptable progression, or withdrawal 
of consent.  Subjects who discontinue either abemaciclib or nivolumab may remain on study.  Subjects with 

Abemaciclib and Nivolumab for HCC 
Page 14 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
radiographic progression with clinical stability may continue on treatment and have repeat imaging in 4-8 
weeks per iRECIST criteria [15] (see section 7.10.5.3 for details). 
3.4 
Study Endpoints 
3.4.1 
Primary Study Endpoint 
The primary study endpoint is overall response rate by investigator review using RECIST v. 1.1 
3.4.2 
Secondary Study Endpoints 
1. Toxicity rates is an ordinal measure, graded using CTCAE v. 5.0, or dichotomized (binary)
2. Overall response rate using iRECIST criteria (binary)
3. Progression-free survival (time to event)
4. Duration of response (time to event)
5. Overall survival (time to event)
4 
Study Population 
4.1 
Inclusion Criteria 
1.
Subjects must have hepatocellular carcinoma (HCC) that is inoperable (where surgery is not indicated
due to disease extent, co-morbidities, or other technical reasons)
2.
Histologic confirmation of HCC is not required for screening but is required prior to initiation of study
treatment.  Subjects with hepatocholangiocarcinoma or cholangiocarcinoma are not eligible.
3.
Tumor must be positive for retinoblastoma (RB) expression by immunohistochemistry
4.
Age > 18 years and ability to understand and the willingness to sign a written informed consent
document.
5.
ECOG performance status of 0 or 1
6.
Childs-Pugh score of <7
7.
Life expectancy of at least 12 weeks
8.
Must be able to swallow tablets
9.
Must be willing to comply with protocol procedures (including completion of diaries and outcome
measures)
10. Local or loco-regional therapy to the liver (i.e. surgery, radiation therapy, hepatic arterial embolization,
chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must
have been completed > 4 weeks prior to enrollment
11. Must be willing to undergo a pretreatment and on-treatment biopsy and have a tumor site that is
accessible for core needle biopsy
12. Measurable or evaluable disease as defined by RECIST v. 1.1
13. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days
of the first dose of abemaciclib (see Appendix A for definition of childbearing potential).  Female
subjects of childbearing potential must use an approved contraceptive method (detailed in Appendix A)
for the duration of the study and an additional 3 weeks after the final dose of abemaciclib.
14. Subjects with hepatitis B must have an HBV viral load < 100 IU/mL by PCR during screening
15. Must have adequate organ and hematopoietic function as defined below:
Table 5: Baseline Laboratory Parameters 
Laboratory Test 
Required Value 
Absolute neutrophil count (ANC) 
> 1.5 x 109/L
Platelet count 
> 75,000 x 109/L
Hemoglobin 
> 8.0 x 109/L

Abemaciclib and Nivolumab for HCC 
Page 15 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
Alanine aminotransferase (ALT) 
< 3 x ULN 
Aspartate aminotransferase (AST) 
< 3 x ULN 
Serum creatinine 
OR creatinine clearance (CrCl) 
< 1.5 x ULN 
OR CrCl > 50mL/min by Cockcroft-Gault Formula 
Total bilirubin 
< 2.0 x ULN 
Serum albumin 
> 2.8 g/dL
INR 
< 1.5 (FFP permitted if elevated) 
4.2 
Exclusion Criteria 
1.
Any history of a serious medical or psychiatric condition that would prevent the subject from signing the
informed consent form
2.
Pregnant or breastfeeding
3.
Use of any chemotherapy within 3 weeks prior to the first study treatment date
4.
Use of any experimental therapy within 4 weeks or 5 half-lives, whichever is longer, prior to the first
study treatment date
5.
Use of radiation within 2 weeks prior to the first study treatment date (4 weeks if radiation to liver as per
section 4.1)
6.
Prior treatment with a CDK 4/6 inhibitor
7.
Prior treatment with a PD-1 or PD-L1 inhibitor
8.
Those who have not recovered from adverse events < Grade 1 from prior therapy, with the exceptions
of alopecia of any grade or stable peripheral neuropathy < Grade 2
9.
Subjects may not receive concomitant anticancer agents or radiation.  Antiviral agents aimed at treating
infectious hepatitis are permitted
10. History of or suspected hypersensitivity to nivolumab or abemaciclib
11. Uncontrolled ascites
12. Esophageal varices requiring treatment within the past 6 months (banding or medication)
13. Subjects with uncontrolled brain metastases.  Subjects with brain metastases must have stable
neurological status following local therapy (surgery or radiation) for at least 4 weeks prior to first study
treatment and must be off of steroids related to the brain metastases.
14. Any concurrent condition requiring the continued or anticipated use of systemic steroids beyond
physiologic replacement dosing (excluding non-systemic inhaled, topical skin, nasal, and/or ophthalmic
corticosteroids).  All other systemic corticosteroids above physiologic replacement dosing must be
discontinued at least 4 weeks prior to first study treatment
15. Active drug or alcohol use or dependence as documented in the chart that, in the opinion of the
investigator, would interfere with adherence to study requirements
16. Active bacterial or fungal infection requiring IV therapy at the start of protocol treatment
17. A second primary malignancy that, in the judgment of the investigator, may affect the interpretation of
results
18. Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the
evaluation of any study endpoint (e.g. interstitial lung disease, severe dyspnea at rest or requiring
oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting
Crohn’s disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or
higher diarrhea)
19. Personal history of ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest
20. Prior organ allograft or allogeneic bone marrow transplantation
21. Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range
with medication

Abemaciclib and Nivolumab for HCC 
Page 16 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
22. Active autoimmune disease, except for vitiligo, type 1 diabetes mellitus, asthma, atopic dermatitis, or
endocrinopathies manageable by hormone replacement; other autoimmune conditions may be
allowable at the discretion of the Principal Investigator
23. Any other conditions judged by the investigator that would limit the evaluation of the subject
24. HIV positive by PCR
4.3 
Subject Recruitment 
Subjects will be identified through the clinical practices of the Abramson Cancer Center and the Hospital of 
the University of Pennsylvania and its affiliated hospitals and through referrals from outside hospitals and 
physicians.  The trial will be publicized on the websites of the Abramson Cancer Center and the Hospital of 
the University of Pennsylvania.  This protocol will also be listed in the ClinicalTrials.gov database.  Subjects 
will be required to give written consent to participate before any screening tests or evaluations are 
conducted. 
4.4 
Total Number of Subjects and Sites 
Twenty-seven evaluable subjects will be enrolled.  Subjects may be enrolled at the University of 
Pennsylvania or at the Penn Presbyterian Medical Center. 
4.5 
Vulnerable Populations 
Children, pregnant women, fetuses, neonates, or prisoners are not included in this research study 
Note: Subjects who become imprisoned or are court-ordered to attend residential alcohol and other drug 
treatment facilities will be considered prisoners under Subpart C of the federal regulations 45CFR46. Such 
subjects cannot be continued in the research unless an amendment to the protocol is submitted and approved 
by the IRB and certification is submitted to the federal Office of Human Research Protections if the research is 
supported by the Department of Health and Human Services. 
5 
Study Intervention
5.1 
Description 
Abemaciclib is an oral tablet that is available in four dosage forms and strengths: 
-50 mg tablets: oval beige table with “Lilly” debossed on one side and “50” on the other side
5.2 
Intervention Regimen 
Abemaciclib will be taken by mouth twice daily 
5.3 
Receipt 
Abemaciclib will be receive to the Investigational Drug Service (IDS) and will be stored at room temperature 
as per standard pharmacy practice  
5.4 
Storage 
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) 
5.5 
Preparation and Packaging 
Abemaciclib is supplied for clinical use in bottles containing 60 tablets  (tablets described in section 5.1). 
5.6 
Administration and Accountability 
Upon completion of study participation or termination of the study, all unused and/or partially-used 
abemaciclib will be destroyed by IDS. 

Abemaciclib and Nivolumab for HCC 
Page 17 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
5.7 
Subject Compliance Monitoring 
Subjects will be required to maintain a pill diary documenting adherence to twice daily oral administration 
of abemaciclib.  Study medication bottles will be brought to study visits at the start of each 28-day cycle 
and study diaries will be reviewed at the start of each cycle. 
6 
Study Procedures 
Table 6: Schedule of Study Procedures 
All labs and study visits have a window of +/- 4 days.  All imaging has a window of +/- 7 days 
Study Phase 
Screening 
Cycle 1 (35 days) 
Cycle 2+ 
(28 days) 
End of 
Study 
Visit2 
Follow-up3 
Study Days 
-28 to 0
1 
8 
151 
291
1 
151 
Treatment 
Abemaciclib 
X------------------------------------------X 
Nivolumab 
X 
X 
Tests and Procedures 
Informed Consent 
X 
Review Inclusion/ 
Exclusion Criteria 
X 
Demographics/Medical 
History 
X 
X3 
Physical Examination 
X 
X 
X 
X 
X 
Vital Signs: BP, HR, RR 
X 
X 
X 
X 
X 
Height 
X 
Weight 
X 
X 
X 
X 
ECOG PS 
X 
X 
X 
X 
X 
Concomitant Medications 
X 
X 
X 
X 
IP Compliance 
X 
X 
AE Assessment 
X 
X 
X 
X 
CBC with differential4 
X 
X 
X 
X 
X 
X 
X4 
X 
Serum Chemistries5 
X 
X 
X 
X 
X 
X 
X5 
X 
TSH 
X 
X 
X 
PT/aPTT6 
X 
X6 
X6 
Serum Pregnancy Test7 
X 
X 
X 
X 
AFP8
X 
X8 
X8 
X8 
HIV Screening9
X 
Hepatitis B/C Screening10
X 
X10 
X10 
X10 
Disease Assessment 
(CT or MRI)11 
X 
X 
X 
Research Correlates 
Blood sample (50cc)12 
X 
X 
X12 
X 
X 

Abemaciclib and Nivolumab for HCC 
Page 18 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
Tumor biopsy13
X 
X 
0F* 
1 Lab visit only 
2 Should occur within 30 days of end of protocol therapy 
3 Follow-up will be through review of the available medical record and/or phone calls every 6 months for up to 2 years 
4 CBC with differential including hemoglobin, white blood count, absolute neutrophil count, and platelet count.  CBC will 
be repeated on day 15 of cycle 2 but is required on day 15 of subsequent cycles only if hematologic toxicity > Grade 2 
by CTCAE v 5.0 
5 Serum chemistries including sodium (Na), potassium (K), chloride (Cl), bicarbonate (HCO3), blood urea nitrogen 
(BUN), creatinine (Cr), albumin, total bilirubin, AST, ALT, and alkaline phosphatase.  Chemistries will be repeated on 
day 15 of cycle 2 but are required on day 15 of subsequent cycles only if hepatotoxicity > Grade 1 by CTCAE v 5.0 or 
other toxicity measured by the panel > Grade 2 by CTCAE v 5.0 are present on day 1 of that cycle. 
6PT/INR will be done at screening, day 1 of cycle 2 and subsequent cycles, and at the end of study visit.  Activated 
thromboplastin time (aPTT) is required only at screening 
7Women of childbearing potential per Appendix A 
8AFP will be repeated only if abnormal at screening 
9HIV screening with HIV1/2 antibody screening and HIV RNA PCR if antibody screen positive 
10Hepatitis B screening with hepatitis B surface antigen, surface antibody, and core antibody (IgG or total antibody, not 
IgM); if hepatitis B surface antigen or core antibody is positive, HBV DNA PCR will be performed.  Hepatitis C screening 
with HCV antibody; if positive, HCV RNA PCR will be performed.  Subjects who are positive for HBV core antibody 
and/or surface antigen at screening must have HBV viral load checked on day 1 of each cycle and at the end of 
treatment visit. 
11Baseline imaging assessment to be performed within 21 days of cycle 1 day 1.  Subsequent imaging on cycle 3 day 
1 and on day 1 of every other subsequent cycle (cycles 5, 7, etc.), and at end of study visit if not performed within prior 
28 days. 
12 Baseline research blood samples can be drawn during screen or prior to treatment on cycle 1 day 1, then on cycle 1 
day 8 prior to nivolumab treatment, cycle 1 day 15-19 (on same day as research tumor biopsy when possible), day 1 
of each subsequent cycle, and at the end of study visit.  Procedures for sample handling are described in the laboratory 
manual. 
13Core or surgical tumor biopsy must occur at baseline after completion of most recent therapy and between days 15 
and 19 of cycle 1.  Biopsies outside of this window for scheduling, safety, or other reasons will not be considered 
deviations but should be discussed with the Principal Investigator. 

Abemaciclib and Nivolumab for HCC 
Page 19 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
6.1 
Screening (Within 28 days of First Dose) 
•
Signed written and informed consent
•
Review and confirm all inclusion/exclusion criteria
•
Complete medical history and demographics
•
Complete physical examination including but not limited to: height, weight, vital signs (oxygen
saturation, heart rate, respiration rate, blood pressure, and oral temperature)
•
ECOG performance status
•
Concomitant medications
•
Clinical laboratory testing including but not limited to:
o
CBC with differential and platelet count
o
Serum chemistries: sodium (Na), potassium (K), chloride (Cl), bicarbonate (HCO3), blood
urea nitrogen (BUN), creatinine (Cr), calcium (Ca), albumin (Alb), total serum bilirubin (TBili),
AST (SGOT), ALT (SPGT), alkaline phosphatase (ALP)
o
Prothrombin time (PT)/International normalized ratio (INR)
o
Activated thromboplastin time (aPTT)
o
Thyroid stimulating hormone (TSH)

If abnormal, free thyroxine will be performed
•
Alpha fetoprotein (AFP)
•
HIV serology
o
HIV 1/2 antibody screen; HIV viral load by PCR if antibody screen positive
•
Serum pregnancy test for beta HCG (for women of childbearing potential, defined in Appendix A)
•
Serologic testing for hepatitis C and hepatitis B:
o
Hepatitis B screening with hepatitis B surface antigen, surface antibody, and core antibody
(IgG or total antibody, not IgM); if hepatitis B surface antigen or core antibody is positive,
HBV DNA PCR will be performed
o
Hepatitis C screening with HCV antibody; if positive, HCV RNA PCR will be performed.  HCV
RNA PCR can also be performed on cycle 1 day 1, and results are not required prior to
initiating therapy.
o
For subjects known to be positive for hepatitis B or hepatitis C by medical history, viral PCR
should be performed concurrently to antibody studies
•
Blood draw (50cc) for correlative research studies (procedures described in laboratory manual)
•
Per standard of care, baseline imaging including but not limited to chest CT (with or without contrast)
and triphasic abdominopelvic CT or MRI, if subject does not have previous documentation within 3
weeks of first dose
•
Core or surgical tumor biopsy (procedures described in laboratory manual)
6.2 
Study Intervention Phase 
All labs and study visits have a window of +/- 4 days.  All imaging has a window of +/- 7 days 
6.2.1 
Cycle 1 
6.2.1.1 
Day 1 - Baseline Visit 
•
Focused physical exam
•
Vital signs and weight
•
ECOG PS
•
CBC with differential and platelet count and serum chemistries (Na, K, Cl, HCO3, BUN, Cr, Ca, Alb,
TBili, AST, ALT, ALP)
•
AFP (only if elevated at screening)
•
Serum pregnancy test for beta HCG (for women of childbearing potential, defined in Appendix A)
•
Review of concomitant medications
•
HCV and HBV viral PCR if indicated:
o
HBV DNA PCR only if hepatitis B surface antigen or core antibody positive
o
HCV RNA PCR if hepatitis C antibody positive and not performed at screening
•
Dispensing of abemaciclib

Abemaciclib and Nivolumab for HCC 
 
Page 20 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
• 
Baseline AE assessment 
 
6.2.1.2 
Day 8 
• 
Focused physical exam 
• 
Vital signs and weight 
• 
ECOG PS 
• 
CBC with differential and platelet count and serum chemistries (Na, K, Cl, HCO3, BUN, Cr, Ca, Alb, 
TBili, AST, ALT, ALP) 
• 
Blood draw (50cc) for correlative research studies (procedures described in laboratory manual) 
• 
AE assessment 
• 
Nivolumab treatment 
 
6.2.1.3 
Day 15 (biopsy and lab visit when possible on same day between days 15 and 19) 
• 
CBC with differential and platelet count and serum chemistries (Na, K, Cl, HCO3, BUN, Cr, Ca, Alb, 
TBili, AST, ALT, ALP) 
• 
Core or surgical tumor biopsy (procedures described in laboratory manual) 
• 
Blood draw (50cc) for correlative research studies (procedures described in laboratory manual) 
 
6.2.1.4 
Day 29 (lab visit only) 
• 
CBC with differential and platelet count and serum chemistries (Na, K, Cl, HCO3, BUN, Cr, Ca, Alb, 
TBili, AST, ALT, ALP) 
 
6.2.2 
Cycle 2 
6.2.2.1 
Day 1 
• 
Focused physical exam 
• 
Vital signs and weight 
• 
ECOG PS 
• 
CBC with differential and platelet count and serum chemistries (Na, K, Cl, HCO3, BUN, Cr, Ca, Alb, 
TBili, AST, ALT, ALP) 
• 
TSH 
• 
PT/INR 
• 
AFP (only if elevated at screening) 
• 
Serum pregnancy test for beta HCG (for women of childbearing potential, defined in Appendix A) 
• 
HBV DNA PCR if hepatitis B surface antigen or core antibody previously positive 
• 
Review of concomitant medications 
• 
Review of abemaciclib pill diary 
• 
Dispensing of abemaciclib and return of unused pills 
• 
AE assessment 
• 
Nivolumab treatment 
• 
Blood draw (50cc) for correlative research studies (procedures described in laboratory manual) 
 
6.2.2.2 
Day 15 (lab visit only) 
• 
CBC with differential and platelet count and serum chemistries (Na, K, Cl, HCO3, BUN, Cr, Ca, Alb, 
TBili, AST, ALT, ALP) 
 
6.2.3 
Cycle 3 and beyond 
6.2.3.1 
Day 1 
• 
Focused physical exam 
• 
Vital signs and weight 
• 
ECOG PS 
• 
CBC with differential and platelet count and serum chemistries (Na, K, Cl, HCO3, BUN, Cr, Ca, Alb, 
TBili, AST, ALT, ALP) 
• 
TSH 

Abemaciclib and Nivolumab for HCC 
Page 21 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
•
PT/INR
•
AFP (only if elevated at screening)
•
Serum pregnancy test for beta HCG (for women of childbearing potential, defined in Appendix A)
•
HBV DNA PCR if hepatitis B surface antigen or core antibody previously positive
•
Review of concomitant medications
•
Review of abemaciclib pill diary
•
Dispensing of abemaciclib and return of unused pills
•
AE assessment
•
Nivolumab treatment
•
Blood draw (50cc) for correlative research studies (procedures described in laboratory manual)
•
Disease assessment (CT or MRI) with 7 days of day 1 of cycle 3, 5, and every other subsequent
cycle
6.2.4 
End of Study Visit (within 30 days of end of protocol therapy) 
•
Focused physical exam
•
Vital signs and weight
•
ECOG PS
•
CBC with differential and platelet count and serum chemistries (Na, K, Cl, HCO3, BUN, Cr, Ca, Alb,
TBili, AST, ALT, ALP)
•
TSH
•
AFP (only if elevated at screening)
•
Serum pregnancy test for beta HCG (for women of childbearing potential, defined in Appendix A)
•
HBV DNA PCR if hepatitis B surface antigen or core antibody previously positive
•
Review of concomitant medications
•
Review of abemaciclib pill diary
•
Return of unused abemaciclib pills
•
AE assessment
•
Blood draw (50cc) for correlative research studies (procedures described in laboratory manual)
•
Disease assessment (CT or MRI) if not performed within prior 28 days
The end of study visit can be conducted during a scheduled office visit (such as to review scans 
demonstrating progression) or separately. 
6.2.5 
Follow-Up Phase of the Study 
All subjects will be followed for survival, disease status and new anti-cancer treatment information unless 
the subject requests to be withdrawn from follow-up or the study is terminated by the Principal Investigator. 
Follow-up information will be collected via telephone or subject medical records until death, loss to follow-
up, or study termination by the Prinicipal Investigator, whichever occurs first. Subjects will be followed every 
6 months up for a maximum of 24 months from the end of protocol therapy. If the subject no longer wishes 
to be contacted but maintains his or her consent, the study staff may use a public information source (e.g. 
newspaper or electronic obituary, county records) to obtain information about survival status only as per 
local data protection laws and approval from the relevant ethics committee. 
6.2.6 
Subject Withdrawal 
Subjects may withdraw from the study at any time without impact to their care.  They may also be 
discontinued from the study at the discretion of the Investigator for lack of adherence to intervention or 
study procedures or visit schedules or unacceptable toxicity of the therapy.  The Investigator may also 
withdraw subjects who violate the study plan, or to protect the subject for reasons of safety or for 
administrative reasons.  It will be documented whether or not each subject completes the clinical study. 
Subjects who withdraw early will have one final visit to collect investigational product and to follow up 
regarding adverse events.  
If a subject permanently discontinues all study treatment for reasons other than disease progression, such 
as toxicity, the state of disease in terms of progression should be noted at this time point. Ideally formal 

Abemaciclib and Nivolumab for HCC 
Page 22 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
imaging should occur at this point to document the state of disease. Alternatively, the previous scan should 
be used. Where possible scanning should continue as per normal practice (RECIST v1.1) until progression 
has been reached as per protocol or the subject has started other anti-cancer treatment. The date of 
progression of disease should be recorded in the eCRF. Further treatment is at the treating doctor’s 
discretion. 
6.2.7 
Data Collection and Follow-Up for Withdrawn Subjects 
Subjects who withdraw consent to participate in the study will be seen for one final visit to collect the 
investigational product. During this visit they will be asked for permission to have the study team look into 
their survival status via publicly available means.   
7 
Study Evaluations and Measurements
7.1 
Informed Consent 
Study personnel will obtain written informed consent from each subject prior to participation in this study, 
following adequate explanation of the aims, eligibility criteria, treatment and follow-up procedures, 
anticipated benefits and potential risks of the study. 
7.2 
Medical History and Demographic Data 
A complete medical history will be obtained including details of any relevant medical conditions occurring 
prior to consent.  Details will be collected on the subject’s cancer diagnosis including site, date of diagnosis, 
radiological tumor size, prior anti-cancer treatment (if any) and outcome, medications and their indications, 
history of alcohol use, history of viral hepatitis (including prior and/or ongoing treatments and current 
disease status), history of non-alcoholic steatohepatitis (NASH), history of autoimmune liver disease, 
history of liver cirrhosis, and Child-Pugh score.  Demographic data collected will include sex, date of birth 
and race/ethnicity. 
7.3 
Physical Examination 
A complete physical examination will be conducted at specified visits.  A focused physical assessment will 
be performed at other visits as determined by the Investigator or directed per subject complaints 
7.4 
Vital Signs, Height, and Weight 
Vital signs including oxygen saturation, heart rate, respiration rate, blood pressure, and oral temperature 
will be measured at specified visits.  Height will be collected at the baseline or screening visit.  Weight will 
be collected at specified visits. 
7.5 
ECOG Performance Status 
ECOG performance status will be measured at specified visits according to Table 7 
Table 7: ECOG Performance Status 
ECOG 
Grade 
ECOG Status 
0 
Fully active, able to carry on all pre-disease 
performance without restriction 
1 
Restricted in physically strenuous activity but 
ambulatory and able to carry out work of a 
light or sedentary nature, e.g., light house 
work, office work 

Abemaciclib and Nivolumab for HCC 
 
Page 23 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
2 
Ambulatory and capable of all self-care but 
unable to carry out any work activities. Up 
and about more than 50% of waking hours 
3 
Capable of only limited self-care, confined to 
bed or chair more than 50% of waking hours 
4 
Completely disabled. Cannot carry on any 
self-care. Totally confined to bed or chair 
5 
Dead 
7.6 
Concomitant Medications 
All medications (including prescription medications and over the counter preparations), taken by the subject 
from the day of consent to the safety visit will be documented as concomitant medications. All medication 
should be recorded to clearly allow identification of prohibited medications. If a subject is taking any of the 
medications defined as prohibited for use during the study, then these will be documented during screening. 
Subjects must stop taking any prohibited medications prior to starting study treatment within the specified 
wash out periods of the prohibited medications. The following details will be collected: drug name, reason 
for treatment, dose/units, route of administration, frequency, start and end date of therapy.  
 
Patients must be instructed not to take any medications, including over-the-counter products such as 
vitamins, minerals and other dietary supplements, without first consulting the Investigator. All concomitant 
medications must be recorded on the relevant eCRF. 
 
Supportive care and other medication, which is considered necessary for the patient’s safety and well-
being, may be given at the discretion of the investigator and recorded in the relevant eCRF.  
 
Patients who use oral contraceptives, hormone replacement therapy, prophylactic or therapeutic 
anticoagulation therapy (such as low molecular weight heparin or warfarin at a stable dose level), or other 
allowed maintenance therapy should continue their use. 
 
Abemaciclib is predominantly cleared by oxidative metabolism via CYP3A4.  Clinical drug interaction 
studies with a CYP3A inhibitor and CYP3A inducer significantly altered the PK of abemaciclib and its 
circulating major metabolites. Therefore, drugs that are strong and moderate inducers of CYP3A and/or 
strong inhibitors of CYP3A should be avoided or substituted if necessary.  
 
If concomitant use cannot be avoided, abemaciclib dose adjustments may be required:  
• 
Patients who must take CYP3A inhibitors such as clarithromycin, diltiazem, or verapamil should reduce 
the abemaciclib dose to 100 mg twice daily.  
• 
Patients who must take itraconazole should reduce the abemaciclib dose to 50 mg twice daily.  
• 
Patients should avoid using ketoconazole  
• 
Patients should avoid grapefruit or grapefruit juice. 
7.7 
Laboratory Evaluations 
Blood samples will be taken to be tested in the clinical laboratory at intervals specified in Table 4 
 
Complete Blood Count: 
White blood cell (WBC) count with differential, hemoglobin, hematocrit, and platelet count 
 
Serum Chemistry: 
Sodium (Na), potassium (K), chloride (Cl), bicarbonate (HCO3), calcium (Ca), blood urea nitrogen (BUN), 
creatinine (Cr), total bilirubin(Tbili), alkaline phosphatase (ALP), AST (SGOT), ALT (SGPT), albumin (Alb) 
 
Coagulation Studies (Screening only): 
Prothrombin time (PT) with international normalized ratio (INR), activated thromboplastin time (aPTT) 

Abemaciclib and Nivolumab for HCC 
 
Page 24 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
 
Tumor Markers: 
Alpha fetoprotein (AFP).  Repeat per Table 6 schedule only if abnormal at screening. 
 
Thyroid Stimulating Hormone (TSH): 
Thyroid stimulating hormone (TSH); if abnormal, check free thyroxine (T4) 
 
Viral Hepatitis Serology and PCR(Screening Only): 
Hepatitis B surface antigen (HbSAg), hepatitis B surface antibody (HbSAb), hepatitis B core antibody 
(HbCAb) total or IgG (IgM only not acceptable), hepatitis C antibody (HCV Ab); if HbSAg or HbCAb positive, 
check HBV viral load; if HCV Ab positive, check HCV viral load. 
 
Subjects with active hepatitis B and/or hepatitis C are eligible for the study but viral status must be verified 
using these screening tests.  Testing must be sent but results are not required prior to the initiation of study 
therapy.  For subjects known to be positive for hepatitis B or hepatitis C by medical history or prior available 
laboratory data, viral PCR may be checked concurrently with viral serologies at screening. 
 
For subjects positive for hepatitis B (surface antigen or core antibody positive), HBV viral PCR will be 
checked on day 1 of every cycle and at the end of treatment visit. 
 
HIV (Screening only): 
HIV 1/2 antibody; if positive, check HIV viral load by PCR.  Subjects with detectable HIV viral RNA by PCR 
are not eligible. 
7.8 
Pregnancy Testing 
A serum pregnancy test will be performed at specified visits for female subjects of childbearing potential as 
defined in Appendix A.  Female subjects of reproductive potential should use a highly effective means of 
contraception (see Appendix A) for the duration of the study and at least 3 weeks after the last dose of 
abemaciclib 
7.9 
Investigational Product Compliance 
Subjects will maintain a diary documenting adherence to abemaciclib.  This diary will be reviewed at the 
start of each treatment cycle (starting with cycle 2) and at the end of study visit. 
7.10 Disease Assessments 
7.10.1 Antitumor Effect 
For the purpose of this study, patients will be evaluated for response every 8 weeks by CT scan of the chest 
with or without contrast and triphasic (non-contrast, arterial phase contrast, venous phase contrast) CT 
scan and/or MRI of the abdomen with IV contrast (pelvis required only if disease documented in pelvis on 
baseline scan).  MRI scans of the abdomen are preferred if the patient is eligible to have this done.  The 
same imaging modality should be used throughout the study. 
 
7.10.2 Definition of Evaluable 
Evaluable for toxicity: All patients will be evaluable for toxicity from the time of their first treatment with 
abemaciclib. 
 
Evaluable for efficacy endpoints, including overall response: Only those patients who have measurable 
disease present at baseline, have received at least one cycle of therapy (including at least 50% of scheduled 
abemaciclib doses and at least 1 dose of nivolumab), and have had their disease re-evaluated by 
appropriate imaging after at least 4 and no more than 12 weeks from cycle 1 day 1 will be considered 
evaluable for efficacy endpoints including overall response. These patients will have their response 
classified according to the definitions stated below. 
 
7.10.3 Disease Parameters 

Abemaciclib and Nivolumab for HCC 
 
Page 25 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
Measurable disease: Measurable lesions are defined as those that can be accurately measured in at least 
one dimension (longest diameter to be recorded) as >20 mm by chest x-ray, as >10 mm with CT scan, or 
>10 mm with calipers by clinical exam. All tumor measurements must be recorded in millimeters (or decimal 
fractions of centimeters).  
Note: Tumor lesions that are situated in a previously irradiated area might or might not be considered 
measurable.  
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node must be 
>15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater 
than 5 mm). At baseline and in follow-up, only the short axis will be measured and followed.  
Non-measurable disease: All other lesions (or sites of disease), including small lesions (longest diameter 
<10 mm or pathological lymph nodes with ≥ 10 to <15 mm short axis), are considered non-measurable 
disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis 
cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by CT or MRI), are 
considered as non-measurable. 
Note: Cystic lesions that meet the criteria for radiographically defined simple cysts should not be considered 
as malignant lesions (neither measurable nor non-measurable) since they are, by definition, simple cysts.  
‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if they 
meet the definition of measurability described above. However, if non-cystic lesions are present in the same 
patient, these are preferred for selection as target lesions. 
Target lesions. All measurable and/or evaluable lesions up to a maximum of 2 lesions per organ and 5 
lesions in total, representative of all involved organs, should be identified as target lesions and recorded 
and measured at baseline. Target lesions should be selected on the basis of their size (lesions with the 
longest diameter), be representative of all involved organs, but in addition should be those that lend 
themselves to reproducible repeated measurements. It may be the case that, on occasion, the largest lesion 
does not lend itself to reproducible measurement in which circumstance the next largest lesion which can 
be measured reproducibly should be selected. In subjects who have received locoregional therapy to the 
liver, lesions that have not been treated locally should be preferentially chosen as target lesions.  If a liver 
lesion that has been treated using locoregional therapy must be chosen as a target lesion, progression of 
the lesion is required after locoregional therapy, A sum of the diameters (longest for non-nodal lesions, 
short axis for nodal lesions) for all target lesions will be calculated and reported as the baseline sum 
diameters. If lymph nodes are to be included in the sum, then only the short axis is added into the sum. The 
baseline sum diameters will be used as reference to further characterize any objective tumor regression in 
the measurable dimension of the disease.  
Non-target lesions. All other lesions (or sites of disease) including any measurable lesions over and above 
the 5 target lesions should be identified as non-target lesions and should also be recorded at baseline. 
Measurements of these lesions are not required, but the presence, absence, or in rare cases unequivocal 
progression of each should be noted throughout follow-up.  
7.10.4 Methods for Evaluation of Measurable Disease 
Clinical lesions: Clinical lesions will only be considered measurable when they are superficial (e.g., skin 
nodules and palpable lymph nodes) and ≥10 mm diameter as assessed using calipers (e.g., skin nodules). 
In the case of skin lesions, documentation by color photography, including a ruler to estimate the size of 
the lesion, is recommended.  

Abemaciclib and Nivolumab for HCC 
Page 26 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
Conventional CT and MRI: This guideline has defined measurability of lesions on CT scan based on the 
assumption that CT slice thickness is 5 mm or less. If CT scans have slice thickness greater than 5 mm, 
the minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable. 
7.10.5 Response Criteria 
7.10.5.1 Evaluation of Target Lesions (RECIST 1.1) 
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether 
target or non-target) must have reduction in short axis to <10 mm.  
Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as 
reference the baseline sum diameters  
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In 
addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 
mm. (Note: the appearance of one or more new lesions is also considered progressions).
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, 
taking as reference the smallest sum diameters while on study. 
7.10.5.2 Evaluation of Non-Target Lesions 
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether 
target or non-target) must have reduction in short axis to <10 mm.  
Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as 
reference the baseline sum diameters  
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In 
addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 
mm. (Note: the appearance of one or more new lesions is also considered progressions).
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, 
taking as reference the smallest sum diameters while on study. 
7.10.5.3 Immune-Related Response in Measurable Lesions (iRECIST) 
iRECIST guidelines were established in 2017 to guide response assessments in clinical trials testing 
immunotherapeutics.  Full details of the iRECIST criteria for this study can be found in Seymour L et al, 
Lancet Oncology 2017 [15].   
If initial RECIST 1.1-defined progression (ie, iUPD) is noted on imaging in the setting of clinical stability, 
subjects may remain on study treatment and have confirmatory imaging in 4-8 weeks (study specified scans 
every 8 weeks should continue on initial schedule if patient remains on study).  An assignment of clinical 
stability requires that no worsening of performance status has occurred, that no clinically relevant increases 
in disease-related symptoms such as pain or dyspnea occur that are thought to be associated with disease 
progression, and that no requirement for intensified management of disease-related symptoms exists, 
including increased analgesia, radiotherapy, or other palliative care.  The imaging findings and the 
recommendation to continue with treatment despite iUPD should be discussed with the patient before a 
decision is made about whether or not to continue therapy. Patients who have iUPD and are not clinically 
stable should be designated as not clinically stable in the case report form. This designation will allow the 

Abemaciclib and Nivolumab for HCC 
 
Page 27 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
best overall response to be calculated and the date of iUPD to be used in estimates of progression-free 
survival. 
If radiologic progression is confirmed (iCPD), they will be determined to have progressive disease and 
discontinued from study therapy, but if repeat imaging shows stable disease or response by RECIST 1.1 
they may remain on study therapy with imaging continuing as previously scheduled every 8 weeks (cycle 3 
day 1, cycle 5 day 1, etc.). 
Table 3: Comparison of RECIST 1.1 and iRECIST 
 
RECIST 1.1 
iRECIST 
Definitions of measurable and 
non-measurable 
disease; 
numbers and site of target 
disease 
Measurable lesions are ≥10 mm 
in diameter (≥15 mm for nodal 
lesions); maximum of five lesions 
(two per organ); all other disease 
is considered non-target (must 
be ≥10 mm in short axis for nodal 
disease) 
No change from RECIST 1.1; 
however, 
new 
lesions 
are 
assessed as per RECIST 1.1 but 
are recorded separately on the 
case 
report 
form 
(but 
not 
included in the sum of lesions for 
target 
lesions 
identified 
at 
baseline) 
Complete 
response, 
partial 
response, or stable disease 
Cannot have met criteria for 
progression 
before 
complete 
response, partial response, or 
stable disease 
Can have had iUPD (one or more 
instances), but not iCPD, before 
CR, PR, or SD 
New lesions 
Result in progression; recorded 
but not measured 
Results in iUPD but iCPD is only 
assigned on the basis of this 
category if at next assessment 
additional new lesions appear or 
an increase in size of new lesions 
is seen (≥5 mm for sum of new 
lesion target or any increase in 
new 
lesion 
non-target); 
the 
appearance of new lesions when 
none 
have 
previously 
been 
recorded, can also confirm iCPD 
Confirmation of progression 
Not required (unless equivocal) 
Required 
Consideration of clinical status 
Consideration of clinical status 
Clinical stability is considered 
when 
deciding 
whether 
treatment is continued after iUPD 
“i” indicates immune responses assigned using iRECIST. RECIST=Response Evaluation Criteria in Solid Tumours. 
iUPD=unconfirmed progression. iCPD=confirmed progression. iCR=complete response. iPR=partial response. 
iSD=stable disease. 
Table 4: Assignment of timepoint response using iRECIST 
 
Timepoint response with no 
previous iUPD in any category 
Timepoint 
response 
with 
previous iUPD in any category 
Target lesions: i CR; non-target 
lesions: iCR; new lesions: no 
iCR 
iCR 
Target lesions: iCR; non-target 
lesions: non-iCR/non-iUPD; new 
lesions: no 
iPR 
iPR 
Target lesions: iPR; non-target 
lesions: non-iCR/non-iUPD; new 
lesions: no 
iPR 
iPR 

Abemaciclib and Nivolumab for HCC 
Page 28 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
Target lesions: iSD; non-target 
lesions: non-iCR/non-iUPD; new 
lesions: no 
iSD 
iSD 
Target lesions: iUPD with no 
change, or with a decrease from 
last timepoint; non-target lesions: 
iUPD 
with 
no 
change, 
or 
decrease from last timepoint; 
new lesions: yes 
Not applicable 
New lesions confirm iCPD if new 
lesions were previously identified 
and they have increased in size 
(≥5 mm in sum of measures for 
new lesion target or any increase 
for new lesion non-target) or 
number; if no change is seen in 
new lesions (size or number) 
from last timepoint, assignment 
remains iUPD 
Target lesions: iSD, iPR, iCR; 
non-target lesions: iUPD; new 
lesions: no 
iUPD 
Remains iUPD unless iCPD is 
confirmed on the basis of a 
further increase in the size of 
non-target disease (does not 
need to meet RECIST 1.1 criteria 
for unequivocal progression) 
Target lesions: iUPD; non-target 
lesions: non-iCR/non-iUPD, or 
iCR; new lesions: no 
iUPD 
Remains iUPD unless iCPD is 
confirmed on the basis of a 
further 
increase 
in 
sum 
of 
measures ≥5 mm; otherwise, 
assignment remains iUPD 
Target lesions: iUPD; non-target 
lesions: iUPD; new lesions: no 
iUPD 
Remains iUPD unless iCPD is 
confirmed based on a further 
increase in previously identified 
target lesion iUPD in sum of 
measures >5 mm or non-target 
lesion 
iUPD 
(previous 
assessment 
need 
not 
have 
shown unequivocal progression) 
Target lesions: iUPD; non-target 
lesions: iUPD; new lesions: yes 
iUPD 
Remains iUPD unless iCPD is 
confirmed on the basis of a 
further increase in previously 
identified target lesion iUPD sum 
of measures ≥5 mm, previously 
identified non-target lesion iUPD 
(does 
not 
need 
to 
be 
unequivocal), or an increase in 
the size or number of new lesions 
previously identified 
Target lesions: non-iUPD or 
progression; non-target lesions: 
non-iUPD or progression; new 
lesions: yes 
iUPD 
Remains iUPD unless iCPD is 
confirmed on the basis of an 
increase in the size or number of 
new lesions previously identified 
Target lesions, non-target lesions, and new lesions defined according to RECIST 1.1 principles; if no 
pseudoprogression occurs, RECIST 1.1 and iRECIST categories for complete response, partial response, and stable 
disease would be the same. 
*Previously identified in assessment immediately before this timepoint. “i” indicates immune responses assigned using
iRECIST. iCR=complete response. iPR=partial response. iSD=stable disease. iUPD=unconfirmed progression. non-
iCR/non-iUPD=criteria for neither CR nor PD have been met. iCPD=confirmed progression. RECIST=Response
Evaluation Criteria in Solid Tumours.

Abemaciclib and Nivolumab for HCC 
 
Page 29 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
7.10.5.4 Overall Response Rate 
Overall response rate is defined as the proportion of subjects who achieve a complete or partial response 
during the course of the study.  The best response experienced by a subject (CR > PR > SD > PD) will be 
used.  Responses will be determined by investigator review.  The primary study endpoint will be use 
RECIST v. 1.1 definitions (sections 7.10.5.1 and 7.10.5.2) to define overall response rate.  Overall response 
rate by iRECIST criteria (section 7.10.5.3) will be a secondary endpoint. 
 
7.10.5.5 Duration of Response 
Duration of Overall Response: The duration of overall response is measured from the time measurement 
criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive 
disease is objectively documented (taking as reference for progressive disease the smallest measurements 
recorded since the treatment started).  
 
The duration of overall CR is measured from the time measurement criteria are first met for CR until the 
first date that progressive disease is objectively documented. 
 
Duration of stable disease: Stable disease is measured from the start of the treatment until the criteria for 
progression are met, taking as reference the smallest measurements recorded since the treatment started, 
including the baseline measurements. 
 
7.10.6 Toxicity Evaluation 
All subjects entered into the study and who are given at least one dose of abemaciclib will have detailed 
information collected on adverse events for the overall study safety analysis. All adverse events will be 
categorized and tabulated using CTCAE v. 5.0. 
 
7.10.7 Progression-Free Survival 
PFS is defined as the duration of time from start of treatment to time of progression using both RECIST v. 
1.1 and iRECIST criteria [15], death, or last patient contact when progression-free. For patients who are 
progression-free, PFS will be censored at the most recent date which documents progression-free status 
(i.e., scan date or clinical visit date). 
 
7.10.8 Overall Survival 
OS is defined as the duration of time from start of treatment to death due to any cause or last patient contact 
alive. Public records (e.g. obituaries) may be used to ascertain dates of death for subjects where such data 
is not available in the medical record unless the subject withdraws consent for follow-up.  For subjects who 
enroll in hospice care in whom the specific date of death cannot be determined, date of death will be 
recorded as the date the patient entered hospice.  In subjects who are alive or lost to follow-up, OS will be 
censored at last date of contact alive. 
7.11 Correlative Studies 
7.11.1 Correlative Blood Samples 
Research blood samples (50cc) will be drawn at baseline, on cycle 1 day 8, cycle 1 day 15, on day 1 of 
each subsequent cycle, and at the end of study visit.  Immune markers such as multi-parameter flow 
cytometry, antigen-specific T-cell assays (to identify tumor-reactive T-cells), markers of APC activation, T-
cell receptor sequencing, and/or cytokine assays will be performed.  Depending on resource and sample 
availability, additional assays to further assess immune activation following treatment will be employed. 
 
Further procedures for handling of research blood samples are described in the laboratory manual. 
7.11.2 Tumor Biopsy 
Tumor tissue samples will be obtained at baseline and between days 15 and 19 of cycle 1.  Biopsies are 
mandatory but can be omitted if in the best interest of the subject after discussion with the Principal 
Investigator.  At a minimum, tissue confirmation of histology (HCC) and RB status by immunohistochemistry 
is required prior to starting study therapy.  Tissue will be analyzed by H&E, and by IHC for PD-L1 and for 

Abemaciclib and Nivolumab for HCC 
 
Page 30 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
immune markers (such as CD45, CD68, CD3, CD8, CD4, Foxp3, CD20, myeloperoxidase), tumor markers 
(AFP, Ki-67, cleaved caspase 3) , vascular (CD31) and stromal markers (collagen type I); and by Masson’s 
trichrome. If sufficient material is available, the tumor may also be assessed by a next-generation 
sequencing panel, whole exome sequencing (WES), RNA sequencing, and/or by other techniques.  When 
tumor WES sequencing, tumor RNAseq, and germline WES is feasible and successfully performed, patient 
specific neo epitopes arising from tumor somatic missense mutations will be predicted bioinformatically. 
 
Depending on resource availability and tissue availability, additional assays to further assess immune 
activation following treatment will be employed. In some cases, germline whole exome sequencing will be 
performed to allow determination of HLA type and as needed for the bioinformatics pipeline to identify 
patient specific neo epitopes.  
 
Further procedures for handling of tumor biopsy material is described in the laboratory manual. 
 
8 
Statistical Plan  
8.1 
Primary Endpoint 
The primary endpoint is overall response rate (ORR) by investigator review using RECIST v. 1.1 (binary).   
8.2 
Secondary Endpoints  
1.  Toxicity rates is an ordinal measure, graded using CTCAE v. 5.0, or dichotomized (binary). 
2.  Overall response rate using iRECIST criteria (binary) 
3.  Progression-free survival (time to event) 
4.  Duration of response (time to event) 
5.  Overall survival (time to event) 
8.3 
Sample Size and Power Determination 
Overall response rate to PD-1 therapy in HCC has varied in published studies from 15-20%.  By combining 
available data from these studies, an overall response rate of 18% is estimated for PD-1 monotherapy.  
Doubling of this response rate, from 18% (H0) to at least 36% (H1) would be highly promising and worthy 
of additional study.  With 27 subjects, a one-sided binomial test with alpha = 0.10 will have 81% power to 
detect an improvement in ORR from 18% (H0) to 36% (H1).  For proportions, a sample of n=27 will provide 
90% confidence intervals that are a maximum of 0.34 in width.  For additional time to event variables, 27 
subjects (21 events by 24 months) yields 90% confidence intervals for median survival that are 
approximately half of mean survival in width (assuming exponential survival).   
8.4 
Statistical Methods 
ORR and other binary variables will be analyzed using binomial exact tests, using a one-sided 10% type 
one error.  Progression-free survival, duration of survival, and overall survival will be analyzed using Kaplan-
Meier methods.  PFS and DOR will be summarized as medians with 90% confidence intervals.  Toxicity 
rates will be summarized as binomial proportions with 90% confidence intervals.  
 
8.4.1 
Baseline Data 
Baseline and demographic characteristics will be summarized by standard descriptive statistics (including 
mean and standard deviation for continuous variables such as age and standard percentages for 
categorical variables such as gender). 
 
8.4.2 
Efficacy Analysis  
To be eligible for efficacy endpoints (PFS, ORR, DOR, OS), subjects must have completed at least one 
cycle of therapy, and have had their disease re-evaluated by appropriate cross-sectional imaging (CT or 
MRI) at least 4 weeks and no more than 12 weeks after their baseline imaging.  Subjects who do not meet 
criteria for the efficacy analysis will be replaced. 
 

Abemaciclib and Nivolumab for HCC 
 
Page 31 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
8.4.3 
Safety Analysis 
All subjects entered into the study and who are given at least one dose of abemaciclib will have detailed 
information collected on adverse events for the overall study safety analysis. All adverse events will be 
categorized by CTCAE v. 5.0,tabulated as ordinal, and summarized as binomial proportions.   
8.4.4 
Exploratory Endpoints 
Analysis of Immune markers in tissue and blood will be a hypothesis-generating exploration of potential 
biomarkers. Logistic regression will be used to evaluate any association of response status with marker, 
and markers will be summarized by response status.  Cox-proportional hazards regression models will be 
used to evaluate for any association with a marker and time to progression 
9 
Safety and Adverse Events 
9.1 
Definitions 
9.1.1 
Unanticipated Problems Involving Risk to Subjects or others 
Any incident, experience, or outcome that meets all of the following criteria: 
• 
Unexpected in nature, severity, or frequency (i.e. not described in study-related documents such as the 
IRB-approved protocol or consent form, the investigators brochure, etc.)  
• 
Related or possibly related to participation in the research (i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by the 
procedures involved in the research)  
• 
Suggests that the research places subjects or others at greater risk of harm (including physical, 
psychological, economic, or social harm).  
9.1.2 
Adverse Event 
An adverse event (AE) is any symptom, sign, illness or experience that develops or worsens in severity 
during the course of the study.  Intercurrent illnesses or injuries should be regarded as adverse events.  
Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality: 
• 
results in study withdrawal 
• 
is associated with a serious adverse event 
• 
is associated with clinical signs or symptoms 
• 
leads to additional treatment or to further diagnostic tests 
• 
is considered by the investigator to be of clinical significance 
9.1.3 
Adverse Events of Special Interest 
AESIs (serious or non-serious) are defined as AEs of scientific and medical concern specific to the 
investigational product or program, for which ongoing monitoring and rapid communication by the Principal 
Investigator to drug manufacturer can be appropriate. Such an event might warrant further investigation in 
order to characterize and understand it. Depending on the nature of the event, rapid communication by the 
Principal Investigator to other parties (e.g., regulators) might also be warranted. 
 
Details on currently agreed list of AESIs for abemaciclib can be found in the current IB. These AESIs are 
to be reported to Eli Lilly expeditiously within 1 business day of knowledge of the event, during the study 
through 30 days after receiving the last dose of study treatment, according to the procedures below 
9.1.4 
Serious Adverse Event 
Serious Adverse Event 
Adverse events are classified as serious or non-serious.  A serious adverse event is any AE that is:  
• 
fatal 
• 
life-threatening 
• 
requires or prolongs hospital stay 
• 
results in persistent or significant disability or incapacity 

Abemaciclib and Nivolumab for HCC 
 
Page 32 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
• 
a congenital anomaly or birth defect 
• 
an important medical event 
 
Important medical events are those that may not be immediately life-threatening, but are clearly of major 
clinical significance.   They may jeopardize the subject and may require intervention to prevent one of the 
other serious outcomes noted above.  For example, drug overdose or abuse, a seizure that did not result 
in in-patient hospitalization, or intensive treatment of bronchospasm in an emergency department would 
typically be considered serious.  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non-serious 
adverse events. 
 
Any AE that results in hospitalization or prolonged hospitalization should be documented and reported as 
an SAE unless specifically instructed otherwise in this protocol. Any condition responsible for surgery 
should be documented as an AE if the condition meets the criteria for an AE. 
 
Neither the condition, hospitalization, prolonged hospitalization, nor surgery are reported as an AE in the 
following circumstances: 
• 
Hospitalization or prolonged hospitalization for diagnostic or elective surgical procedures for a 
preexisting condition. Surgery should not be reported as an outcome of an AE if the purpose of the 
surgery was elective or diagnostic and the outcome was uneventful.  
• 
Hospitalization or prolonged hospitalization required to allow efficacy measurement for the study.  
• 
Hospitalization or prolonged hospitalization for therapy of the target disease of the study, unless it is a 
worsening or increase in frequency of hospital admissions as judged by the clinical investigator. 
 
Events of progression of the subject’s underlying cancer as well as events clearly related to progression of 
the subject’s cancer (signs and symptoms of progression) should not be reported as a serious adverse 
event unless the outcome is fatal within the safety reporting period. If the event has a fatal outcome within 
the safety reporting period, then the event of Progression of Disease must be recorded as an AE and as a 
SAE with CTC Grade 5 (fatal outcome) indicated. 
 
Preexisting Condition 
A preexisting condition is one that is present at the start of the study. A preexisting condition should be 
recorded as an AE if the frequency, intensity, or the character of the condition worsens during the study 
period. 
 
General Physical Examination Finding  
At screening, any clinically significant abnormality should be recorded as a preexisting condition. At the end 
of the study, any new clinically significant findings/abnormalities that meet the definition of an AE must also 
be recorded and documented as an AE. 
 
Abnormal Laboratory Values 
An abnormal laboratory value that is not already associated with an AE is to be recorded as an AE only if 
any one of the following criteria is met: 
• 
an action on the study drug is made as a result of the abnormality 
• 
intervention for management of the abnormality is required 
• 
at the discretion of the investigator should the abnormality be deemed clinically significant 
 
9.2 
Adverse Event Reporting Period 
The study period during which adverse events must be reported is normally defined as the period from the 
initiation of any study procedures to the end of the study treatment follow-up.  For this study, the study 
treatment follow-up is defined as 30 days following the last administration of study treatment. 

Abemaciclib and Nivolumab for HCC 
Page 33 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
9.2.1 
Post-Study Adverse Event 
All unresolved AEs should be followed by the investigator until the events are resolved, the subject is lost 
to follow-up, or the AE is otherwise explained. At the last scheduled visit, the investigator should instruct 
each subject to report any subsequent event(s) that the subject, or the subject’s personal physician, 
believes might reasonably be related to participation in this study. The investigator should notify the 
Principal Investigator of any death or AE occurring at any time after a subject has discontinued or terminated 
study participation that may reasonably be related to this study. The Principal Investigator should also be 
notified if the investigator should become aware of the development of cancer or of a congenital anomaly 
in a subsequently conceived offspring of a subject that has participated in this study. 
9.3 
Recording of Adverse Events 
At each contact with the subject, the investigator will seek information on adverse events by specific 
questioning and, as appropriate, by examination.  Information on all adverse events will be recorded 
immediately in the source document, and also in the appropriate adverse event module of the case report 
form (CRF).  All clearly related signs, symptoms, and abnormal diagnostic procedures results should 
recorded in the source document, though should be grouped under one diagnosis. 
All adverse events occurring during the study period will be recorded.  The clinical course of each event will 
be followed until resolution, stabilization, or until it has been determined that the study intervention or 
participation is not the cause.  Serious adverse events that are still ongoing at the end of the study period 
will be followed up to determine the final outcome.  Any serious adverse event that occurs after the study 
period and is considered to be possibly related to the study intervention or study participation will be 
recorded and reported immediately. 
9.4 
Relationship of AE to Study 
The relationship of each adverse event to the study procedures should be characterized by the Investigator 
as definitely related, probably related, possibly related , unlikely or unrelated to study therapy. 
9.5 
Reporting of Adverse Events, Adverse Device Effects and Unanticipated Problems 
Investigators must conform to the adverse event reporting timelines, formats and requirements of the 
various entities to which they are responsible,  
If the report is supplied as a narrative, the minimum necessary information to be provided at the time of the 
initial report includes: 
Study identifier 
Study Center 
Subject number 
A description of the event 
Date of onset 
Current status 
Whether study intervention was discontinued 
The reason why the event is classified as serious 
Investigator assessment of the association between 
the event and study intervention 
Additionally all other events (unanticipated problems, adverse reactions, unanticipated adverse device 
effects and subject complaints  will be recorded and reported with respect to institutional and federal policies 
as described in the Penn Manual and below.  
9.5.1 
Follow-up report 
If an SAE has not resolved at the time of the initial report and new information arises that changes the 
investigator’s assessment of the event, a follow-up report including all relevant new or reassessed 
information (e.g., concomitant medication, medical history) should be submitted to the IRB. The investigator 
is responsible for ensuring that all SAE are followed until either resolved or stable.  

Abemaciclib and Nivolumab for HCC 
 
Page 34 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
9.5.2 
Investigator Reporting: Notifying Drug Manufacturer (Eli Lilly) 
All SAEs, AESIs, and pregnancies, regardless of relationship to study drug, must be reported to the drug 
manufacturer during the study through 30 days after receiving the last dose of study treatment within 1 
business day, according to the procedures below. After the 30-day specified window, only SAEs considered 
to be treatment related and all AESIs, regardless of treatment relationship, should be reported. It is 
important that the investigator provide an assessment of relationship of the SAE or AESI to study treatment 
at the time of the initial report. 
 
Serious adverse events should be reported to Lilly using a CIOMS Form or other form acceptable to Lilly.  
Investigator and Institution further agree to make available promptly to Lilly such records as may be 
necessary and pertinent for Lilly to further investigate an adverse event in the Study that is possibly 
associated with the Study Drug. 
 
Investigator and Institution agree to provide Lilly with a copy of all information Investigator and/or Institution 
submit to regulators related to any adverse events for the Study Drug that occur during the Study that 
Investigator and/or Institution have not otherwise provided Lilly. 
9.5.3 
Investigator Reporting: Notifying the Penn IRB  
This section describes the requirements for safety reporting by investigators who are Penn faculty, affiliated 
with a Penn research site, or otherwise responsible for safety reporting to the Penn IRB. The University of 
Pennsylvania IRB (Penn IRB) requires expedited reporting of those events related to study participation 
that are unforeseen and indicate that participants or others are at increased risk of harm.  The Penn IRB 
will not acknowledge safety reports or bulk adverse event submissions that do not meet the criteria outlined 
below.  The Penn IRB requires researchers to submit reports of the following problems within 10 working 
days from the time the investigator becomes aware of the event: 
 
Any adverse event (regardless of whether the event is serious or non-serious, on-site or off-site) that occurs 
any time during or after the research study, which in the opinion of the principal investigator is: 
 
Unexpected (An event is “unexpected” when its specificity and severity are not accurately reflected in the 
protocol-related documents, such as the IRB-approved research protocol, any applicable investigator 
brochure, and the current IRB-approved informed consent document and other relevant sources of 
information, such as product labeling and package inserts.) 
 
AND 
 
Related to the research procedures (An event is “related to the research procedures” if in the opinion of the 
principal investigator or sponsor, the event was more likely than not to be caused by the research 
procedures.) 
9.5.4 
Reporting Process 
Unanticipated problems posing risks to subjects or others as noted above will be reported to the Penn IRB 
using the form: “Unanticipated Problems Posing Risks to Subjects or Others Including Reportable Adverse 
Events” or as a written report of the event (including a description of the event with information regarding 
its fulfillment of the above criteria, follow-up/resolution and need for revision to consent form and/or other 
study documentation). 
 
Copies of each report and documentation of IRB notification and receipt will be kept in the Clinical 
Investigator’s study file. 
9.5.5 
Other Reportable Events: 
For clinical drug trials, the following events are also reportable to the Penn IRB: 

Abemaciclib and Nivolumab for HCC 
 
Page 35 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
• 
Any adverse experience that, even without detailed analysis, represents a serious unexpected adverse 
event that is rare in the absence of drug exposure (such as agranulocytosis, hepatic necrosis, Stevens-
Johnson syndrome). 
• 
Any adverse event that would cause the sponsor to modify the investigators brochure, protocol or 
informed consent form, or would prompt other action by the IRB to assure protection of human subjects. 
• 
Information that indicates a change to the risks or potential benefits of the research, in terms of severity 
or frequency. For example:  
o 
An interim analysis indicates that participants have a lower rate of response to treatment than 
initially expected. 
o 
Safety monitoring indicates that a particular side effect is more severe, or more frequent than 
initially expected. 
o 
A paper is published from another study that shows that an arm of your research study is of no 
therapeutic value. 
o 
Change in FDA safety labeling or withdrawal from marketing of a drug, device, or biologic used 
in a research protocol. 
• 
Breach of confidentiality  
• 
Change to the protocol taken without prior IRB review to eliminate apparent immediate hazard to a 
research participant. 
• 
Incarceration of a participant when the research was not previously approved under Subpart C and the 
investigator believes it is in the best interest of the subject to remain on the study. 
• 
Complaint of a participant when the complaint indicates unexpected risks, or the complaint cannot be 
resolved by the research team. 
• 
Protocol violation (meaning an accidental or unintentional deviation from the IRB approved protocol) 
that in the opinion of the investigator placed one or more participants at increased risk, or affects the 
rights or welfare of subjects. 
9.6 
Abramson Cancer Center Data Safety Monitoring Committee (DSMC): 
Every effort should be made to report an event as a diagnosis, not as a list of symptoms. Symptoms that 
led to the diagnosis should be included in the event description but should not be the actual event. 
 
Unless covered by exclusions below, Grade 3 or higher events must be reported within 10 days of 
knowledge. 
 
All unexpected deaths within one business day of knowledge. 
 
All other deaths within 30 days of knowledge. Deaths of subjects off-study for greater than 30 days from 
the last study treatment/intervention are not reportable unless a longer time frame is specified in the 
protocol. 
 
EXCEPTIONS to AE/SAE Reporting: 
 
Grade 3 or 4 events that are judged by a study investigator to be clearly unrelated to protocol therapy.  The 
reason for determining that the event is unrelated must be clearly documented in the EMR. 
 
Grade 3 or 4 events that are probably or definitely related to progression of disease as judged by a study 
investigator. The fact that this event is related to disease progression must be clearly document in the EMR. 
 
Grade 3 or 4 events that are probably or definitely related to an FDA approved agent. The fact that this 
event is related to the FDA approved agent must be clearly documented in the EMR.. 
 
SAEs will be submitted to the DSMC through the Velos Clinical Trial Management System. 
 
Reportable Events; 
 
Exception 

Abemaciclib and Nivolumab for HCC 
 
Page 36 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
A one-time, intentional action (planned prospectively) or process that departs from the IRB and CTSRMC 
approved study protocol, intended for one occurrence. Advance documented IRB and DSMC approval is 
required. 
 
For in-house studies with a Medical Monitor or Safety Monitoring Committee (not DSMB), approval must 
be obtained from the Medical Monitor or Safety Monitoring Committee prior to submitting your exception 
request to the DSMC. 
 
The following information must be contained in your exception request: 
• 
When it is needed and why it is needed in that timeframe 
• 
Has the Medical Monitor or Sponsor approved and provide the documentation of approval 
• 
Is this an exception from eligibility, treatment, disease progression, study calendar windows, etc.  
• 
Why the exception is needed (cite the section(s) of the protocol) along with the full clinical details of the 
subject. This must be determined by the sub-Investigator or PI.  
• 
The reason why the protocol currently doesn't allow the situation for which an exception is being 
requested. This must be determined by the sub-Investigator or PI. 
• 
If there are plans to amend the protocol and if not, why not. 
• 
If additional follow-up or interventions will be required in order to protect the subject as a result of this 
exception. 
 
Study Exceptions the DSMC may Reject: 
 
Exceptions to eligibility, treatment/dosing, contraindicated treatment/therapies/interventions or safety tests 
for the following types of studies may be rejected by the DSMC: 
 
• 
Any investigator-initiated treatment study. 
• 
Any treatment study involving on-campus manufacturing of any component, regardless of sponsor. 
 
To seek approval, you must provide the DSMC with strong and compelling scientific and clinical information 
to support your request. You should also include a statement explaining whether or not the protocol will be 
amended. If the protocol will not be amended your reasoning must be provided. If this situation is likely to 
happen again, the DSMC will require a protocol amendment. 
 
Deviation 
 
Any unintentional action or process that departs from IRB approval and is identified retrospectively. The 
deviation is reportable to the DSMC and the IRB within 10 days from the time the event becomes known to 
the study team only when: one or more participants were placed at increased risk of harm, or, the event 
has the potential to occur again, or the event has the potential to qualify as serious or continuing 
noncompliance. 
 
If the PI determines that a deviation has any potential to impact participant safety (harm and/or risk), or 
the integrity of data produced from the participant, or some other overall impact on the study, the PI must 
report the deviation to the IRB and DSMC as described above. The IRB will make the final assessment of 
the impact. The DSMC will assess for additional safety and scientific integrity concerns. 
 
The following information must be contained in your deviation report: 
• 
When it happened? When the study team (any member) became aware 
• 
The full description of the deviation including important dates, test results, actions taken towards the 
subject, etc. Also, why it happened and how it was identified. 
• 
Was the Medical Monitor or Sponsor notified. If so, their response? 
• 
The PIs assessment of the impact on risk, safety and/or outcome. If no impact, why. If impact, what 
and what will happen next. 
• 
The corrective actions that have been implemented to date and the impact of those corrective action 
plans. 

Abemaciclib and Nivolumab for HCC 
 
Page 37 
Version 09/23/2019 
 
CONFIDENTIAL 
 
This material is the property of the University of Pennsylvania.   
 
• 
Future corrective action plans (if applicable) and the impact of those plans. 
• 
If there are plans to amend the protocol (if applicable to prevent future deviations) and if not, why not. 
 
If the PI determines that the event had no potential to impact participant safety (harm and/or risk) or the 
integrity of data produced from the participant, the PI must fully document his/her rationale for each category 
(risk, harm, and participant data). 
10 Study Administration, Data Handling and Record Keeping 
10.1 Confidentiality 
Information about study subjects will be kept confidential and managed according to the requirements of 
the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Those regulations require a signed 
subject authorization informing the subject of the following:  
• 
What protected health information (PHI) will be collected from subjects in this study  
• 
Who will have access to that information and why 
• 
Who will use or disclose that information 
• 
The rights of a research subject to revoke their authorization for use of their PHI 
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains 
the ability to use all information collected prior to the revocation of subject authorization. For subjects that 
have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect 
at least vital status (i.e. that the subject is alive) at the end of their scheduled study period 
10.2 Data Collection and Management  
This study will use Velos as the data management system.  The study case report form (CRF) is the primary 
data collection instrument for the study and will be electronically created and completed in Velos. CRFs will 
be provided for each subject. Subjects must not be identified by name on any CRFs. Subjects will be 
identified by their subject identification number (PID). All data requested on the CRF must be recorded. All 
missing data must be explained. If a space on the CRF is left blank because the procedure was not done, 
or the question was not asked, write “N/D”. If the item is not applicable to the individual case, write “N/A.”.  
All entries should be printed legibly in black ink.  If any entry error has been made, to correct such an error, 
draw a single straight line through the incorrect entry and enter the correct data above it.  All such changes 
must be initialed and dated.  DO NOT ERASE OR WHITE OUT ERRORS.  For clarification of illegible or 
uncertain entries, print the clarification above the item, then initial and date it.    
11 Study Monitoring, Auditing, and Inspecting 
11.1 Study Monitoring Plan 
It is the responsibility of the Principal Investigator to oversee the safety of the study at his/her site.  This 
safety monitoring will include careful assessment and appropriate reporting of adverse events as noted 
above, as well as the construction and implementation of a site data and safety-monitoring plan.  Medical 
monitoring will include a regular assessment, at least every 6 months, of the number and type of serious 
adverse events by an independent clinician, David Vaughn, MD, Department of Medicine, Division of 
Hematology-Oncology.  Additionally, the Medical Monitor will be consulted for protocol exceptions and 
deviations and as needed for decision-making regarding dose modifications, study eligibility, and any need 
to stop enrollment or the study for safety concerns. 
 
This study will be monitored in accordance with the Cancer Center’s Clinical Trials Scientific Review and 
Monitoring Committee (CTSRMC) Plan, approved by NCI during the Core Grant’s most recent review. This 
plan requires that the investigator submit a study-specific plan outlining how data will be reviewed In 
addition, the CTSRMC plan calls for an internal audit by the Cancer Center’s Data Safety Committee twice 
yearly. The investigator will allocate adequate time for such monitoring activities. The Investigator will also 
ensure that the monitor or other compliance or quality assurance reviewer is given access to all the above 

Abemaciclib and Nivolumab for HCC 
Page 38 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
noted study-related documents and study related facilities (e.g. pharmacy, diagnostic laboratory, etc.), and 
has adequate space to conduct the monitoring visit. 
11.2 Auditing and Inspecting 
The investigator will permit study-related monitoring, audits, and inspections by the IRB, government 
regulatory bodies, and University compliance and quality assurance groups of all study related documents 
(e.g. source documents, regulatory documents, data collection instruments, study data etc.). The 
investigator will ensure the capability for inspections of applicable study-related facilities (e.g. pharmacy, 
diagnostic laboratory, etc.). 
Participation as an investigator in this study implies acceptance of potential inspection by government 
regulatory authorities and applicable University compliance and quality assurance offices. 
12 Ethical Considerations 
This study is to be conducted according to US and international standards of Good Clinical Practice (FDA 
Title 21 parts 50 and 56 and International Conference on Harmonization guidelines), applicable government 
regulations and Institutional research policies and procedures. 
This protocol and any amendments will be submitted to a properly constituted independent IRB, in 
agreement with local legal prescriptions, for formal approval of the study conduct. 
All subjects for this study will be provided a consent form describing this study and providing sufficient 
information for subjects to make an informed decision about their participation in this study.  This consent 
form will be submitted with the protocol for review and approval by the IRB and CTSRMC for the study. 
The formal consent of a subject, using the IRB-approved consent form, must be obtained before that subject 
undergoes any study procedure.  The consent form must be signed by the subject and the investigator-
designated research professional obtaining the consent.  
13 Study Finances 
13.1 Funding Source 
This clinical study, including correlative work, will be supported by funds provided by Eli Lilly 
Pharmaceuticals, Inc. 
13.2 Conflict of Interest 
All University of Pennsylvania Investigators will follow the University of Pennsylvania Policy on Conflicts of 
Interest Related to Research.  
14 Publication Plan 
Neither the complete nor any part of the results of the study carried out under this protocol, nor any of the 
information provided by the sponsor for the purposes of performing the study, will be published or passed 
on to any third party without the consent of the Principal Investigator.  Any investigator involved with this 
study is obligated to provide the Principal Investigator with complete test results and all data derived from 
the study. 
15 References 
1.
Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and
Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From
the Global Burden of Disease Study 2015. JAMA Oncol. 2017 Dec 1;3(12):1683-1691
2.
Siegel RL, Miller KD, Jemal A. (2018), Cancer statistics, 2018. CA: A Cancer Journal for Clinicians,
68: 7–30.

Abemaciclib and Nivolumab for HCC 
Page 39 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
3.
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular
carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and
expansion trial. Lancet. 2017 Jun 24;389(10088):2492-2502.
4.
Zhu AX, Finn RS, Cattan S, et al. KEYNOTE-224: Pembrolizumab in patients with advanced
hepatocellular carcinoma previously treated with sorafenib.  J Clin Oncol 36, 2018 (suppl 4S; abstr
209).
5.
Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017
Aug 24;548(7668):471-475.
6.
Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control
cancer immune surveillance. Nature. 2018 Jan 4;553(7686):91-95.
7.
Teo ZL, Versaci S, Dushyanthen S, et al. Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and
Immunogenic in Triple-Negative Breast Cancer. Cancer Res. 2017 Nov 15;77(22):6340-6352.
8.
Deng J, Wang ES, Jenkins RW, et al. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing
T-cell Activation. Cancer Discov. 2018 Feb;8(2):216-233.
9.
Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 Inhibitor Abemaciclib Induces a T Cell
Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. Cell
Rep. 2018 Mar 13;22(11):2978-2994.
10. Bollard J, Miguela V, Ruiz de Galarreta M, et al. Palbociclib (PD-0332991), a selective CDK4/6
inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 2017
Jul;66(7):1286-1296.
11. Littman SJ, Brus C, Burkart A.  A phase II study of palbociclib (PD-0332991) in adult patients with
advanced hepatocellular carcinoma. J Clin Oncol 33, 2015 (suppl 3: abstr 277).
12. Rugo HS, Kabos P, Dickler MN, et al. A phase 1b study of abemaciclib plus pembrolizumab for
patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative
(HER2-) metastatic breast cancer (MBC). Presented at: 2017 San Antonio Breast Cancer
Symposium; San Antonio, Texas, December 5-9, 2017. Presentation P1-09-01.
13. Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4
and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast
Cancer. Clin Cancer Res. 2017 Sep 1;23(17):5218-5224.
14. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in
Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine
Therapy. J Clin Oncol. 2017 Sep 1;35(25):2875-2884.
15. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials
testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152.

Abemaciclib and Nivolumab for HCC 
Page 40 
Version 09/23/2019 
CONFIDENTIAL 
This material is the property of the University of Pennsylvania. 
16 Appendix A:  Definition of Non-Childbearing Potential and Medically Acceptable Methods of 
Birth Control 
Non-childbearing potential is defined as any of the following (by other than medical reasons): 
1.
≥45 years of age and has not had menses for >2 years
2.
Amenorrhoeic for <2 years without a hysterectomy and oophorectomy and a follicle-stimulating
hormone value in the postmenopausal range upon pre-study (screening) evaluation
3.
Post hysterectomy, oophorectomy or tubal ligation
A female of childbearing potential, must have a negative serum pregnancy test within 7 days of the first 
dose of abemaciclib and agree to use a highly effective contraception method during the treatment period 
and for 3 weeks following the last dose of abemaciclib.   
Acceptable methods include: 
•
Condoms
•
Diaphragm
•
Cervical cap
•
Intra-uterine device
•
Surgical sterilization (tubal ligation or vasectomy)
•
Oral contraceptives
If condoms are used as a barrier method, a spermicidal agent should be added as a double barrier 
protection. 
Cases of pregnancy that occur during maternal exposures to abemaciclib should be reported. If a patient 
is determined to be pregnant following abemaciclib initiation, she must discontinue treatment immediately. 
Data on fetal outcome and breast-feeding are to be collected for regulatory reporting and drug safety 
evaluation. 
Abstinence at certain times of the cycle, such as during ovulation or after ovulation, or withdrawal are not 
acceptable methods.  The list of methods above is not exhaustive and additional contraception methods 
may also be acceptable if approved by the study doctor. 

NCT Number 
NCT03781960 
Protocol 
Official Title 
PHASE II TRIAL OF ABEMACICLIB AND NIVOLUMAB FOR 
SUBJECTS WITH HEPATOCELLULAR CARCINOMA 
Documents 
Included 
UNIVERSITY OF PENNSYLVANIA RESEARCH SUBJECT 
COMBINED INFORMED CONSENT FORM AND HIPAA 
AUTHORIZATION 
Document 
Date 
(mm/dd/yyyy) 
12/14/2019 

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
1 of 19 
 
UNIVERSITY OF PENNSYLVANIA 
RESEARCH SUBJECT  
COMBINED INFORMED CONSENT FORM AND HIPAA AUTHORIZATION 
Protocol Title: 
A PHASE II TRIAL OF ABEMACICLIB AND NIVOLUMAB FOR 
SUBJECTS WITH HEPATOCELLULAR CARCINOMA 
Sponsor Investigator: 
Thomas Karasic, MD 
Abramson Cancer Center of the University of Pennsylvania 
Philadelphia, PA 19104 
215-614-1858
Sub-investigators: 
Mark O’Hara, MD; Kim Reiss-Binder, MD; Ursina Teitelbaum, MD; 
Charles Schneider, MD; Jennifer Eads, MD; Nevena Damjanov, MD; 
Ryan Massa, MD 
Emergency Contact: 
24 Hour Emergency – Call 215-662-4000 for HUP operator 
Ask for Oncologist On-Call 
Why am I being asked to volunteer? 
You are being asked to participate in this research study because you have Hepatocellular Carcinoma 
(HCC). Your participation is voluntary, which means you can choose whether or not you want to 
participate. If you choose not to participate, your clinical care will not be affected. Before agreeing to 
participate in this research study, it is important that you read the following explanation of the proposed 
procedures and how long you will be in the study. This document describes the purpose, procedures, 
benefits, risks, discomforts and precautions of the study. It also describes the alternative procedures that 
are available to you and your right to withdraw from the study at any time.   
Please take time to read the following information carefully. You may wish to discuss it with your family, 
friends, and your personal doctor (i.e., your family doctor or primary care doctor). If you have any 
questions, you may ask your study doctor and/or the research team for more information. Take time to 
decide whether or not you wish to take part. If you decide to participate, you will be asked to sign this form. 
If you decide to participate, you can change your mind at any time and withdraw from the study without 
giving a reason. 
What is the purpose of this research study? What does this study involve? 
The main purpose of this study is: 
•
To evaluate the effectiveness of the combination of nivolumab and abemaciclib for the
treatment of hepatocellular carcinoma
Other goals of this study are: 
•
To learn about the side effects that this combination of drugs may cause
•
To learn more about how these drugs work by studying blood and tissue
During this study you will receive a combination of 2 medications: 
1. Nivolumab (also known as Opdivo) is a cancer therapy that activates the immune system to
attack tumor cells by “removing the brakes” of the immune system.  Nivolumab is FDA-
approved for the treatment of advanced HCC.
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
2 of 19 
 
2. Abemaciclib (also known as Verzenio) is a cancer therapy that slows cancer growth by
preventing cells from dividing.  It has also been shown in laboratory studies to make the
immune system more active.  It is FDA-approved for the treatment of breast cancer but is not
used for the standard treatment of HCC.
Who is sponsoring this study? 
Dr. Thomas Karasic, the Principal Investigator, is also the sponsor (entity responsible for the design, 
conduct and regulatory oversight of the study). Eli Lilly corporation is the manufacturer of the study drug, 
abemaciclib, and will be providing the drug during this research study. Dr. Karasic and the University of 
Pennsylvania will receive payments to cover some of the research costs such as the collecting/reporting 
study information associated with the conduct of the study. 
Conflict of Interest: 
In addition, one or more of the investigators (as listed on page 1 of this consent document) may receive 
extra money from Bristol-Myers Squibb (BMS) for work done which is not part of this study and/or may 
receive extra money from competitor companies who make similar therapies (drugs in the same class as 
the one evaluated in this study).  These activities may include consulting, advisory boards, giving 
speeches or writing reports.  If you would like more information, please ask a member of the research 
team. 
How long will I be in the study? 
You may continue to participate on this study until your disease gets worse, you experience unacceptable 
side effects, and/or your physician no longer believes the therapy is of benefit to you (whichever occurs 
first). 
What am I being asked to do? 
If you meet all of the criteria for being in the study, you will be registered to participate. 
Screening Procedures: These procedures are done to evaluate your cancer, overall health, and eligibility. 
If you have had some of these tests/procedures recently, they may not need to be repeated. These tests 
and procedures need to be done within 28 days before you receive your first dose of study drug, unless 
otherwise indicated.  
•
A review of your history to include:
o
A review of your medical and cancer history to make sure you do not have any conditions
that could interfere with your taking part in this study (this will include the review of results
from genetic testing you have already had)
o
A review of the medications you are taking, including all prescription medications and all
non-prescription medications (such as vitamins, herbal supplements, aspirin, etc.)
o
A review of your social history (such as if you are a smoker and how much alcohol you may
drink)
o
A review of any significant medical or surgical procedures you have had
•
A complete physical examination including height and weight
•
An assessment of how your disease affects your daily living abilities (called Performance Status).
•
Measurement of your vital signs (blood pressure, pulse, and temperature)
•
Prior and concomitant medications and any surgical procedure
•
Approximately 4 teaspoons (tsp) of blood will be drawn to determine your eligibility. The routine
tests being done to determine your eligibility and for safety purposes will test your blood cell counts
(number of each type of blood cell), blood chemistry levels (to test your kidney and liver function
and the minerals in your body), thyroid function, the ability of your blood to clot properly, whether
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC                                              UPCC 35218 (Penn IRB # 832174) 
 
Version:9/18/2019 
  
3 of 19 
 
you have hepatitis B or C, whether you have HIV, and a serum pregnancy test for women of child 
bearing potential.  If the pregnancy test comes back positive you will not be allowed to participate 
in this study. 
o If you test positive for hepatitis B, hepatitis C, or HIV, by law we have to report the positive 
test results to the City of Philadelphia Health Department and/or the PA Department of 
Health. Personal identifiers such as name, sex, date of birth, address, and phone number 
will be reported. For more information about the requirements reporting infectious diseases 
to the City of Philadelphia Health Department, please visit 
https://hip.phila.gov/ReportDisease. For more information about the requirements reporting 
infectious diseases to the PA Health Department, please visit 
http://www.health.pa.gov/Your-Department-of-
Health/Offices%20and%20Bureaus/epidemiology/Pages/Reportable-
Diseases.aspx#.V620aZ3D9eU. 
o In the case of HIV, reporting is used to keep track of how many people in the U.S. have HIV 
infection. It is also to make sure that states get enough money from the federal government 
to support the medical care of people living with HIV.  The Health Department does not 
share the names of HIV infected people with anyone else. It removes all personal 
identifiers, such as your name, before giving information on the number of HIV infections to 
the federal government. 
• 
Approximately 10 teaspoons of blood will be drawn for research purposes 
o This would not typically be done as a part of your standard of care treatment. 
• 
Radiology tests - to assess your disease. These assessments may include a CT (computed 
tomography) scan or MRI (magnetic resonance imaging) scan 
• 
You will be asked to allow your doctor to complete a tumor biopsy and remove a small amount of 
tumor before you start study treatment.  Providing this type of tumor sample is essential in helping 
us learn about your specific disease and how we can help other patients like you.   
o This would not typically be done as a part of your standard of care treatment. 
 
 
Procedures associated with the administration of the study drug(s) 
When all of the above tests/procedures have been completed, you have been found eligible to enter this 
study, and you agree to participate, you will be scheduled to receive study drug.  
 
Treatment will be provided as cycles, with each cycle comprised of 4 weeks (28 days), except for the first 
cycle, which will be 5 weeks (35 days). Cycles will continue until your cancer gets worse, you experience 
unacceptable side effects, your doctor no longer believes the therapy is in your best interest, or you no 
longer want to participate in the study. 
 
Nivolumab will be administered intravenously (IV) into a vein every 4 weeks.  This will require 
approximately 30 minutes to administer in the infusion center. 
 
Abemaciclib will be administered by mouth twice per day every day of each treatment cycle. 
 
You will be given a diary to record when you take your abemaciclib. You will be asked to bring this 
completed diary and your remaining study drug and/or empty pill bottles to each study visit. When you 
return this study drug kit and diary, the study team will review everything to make sure you are taking the 
drug appropriately and completing this diary as requested 
 
Study Tests/Procedures 
These exams, tests, and procedures are being done to evaluate your health and response to the study 
drug(s). At each of these study visits you will be asked how you are feeling, if you have had any side 
effects, if you may be pregnant, if you have had any medical procedures, and about any medications you 
are taking. It is important you check with your study doctor before starting any new medications. Taking 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
4 of 19 
 
other drugs (including alcohol, over-the-counter medications, herbal preparations, illegal drugs, or 
nutritional supplements) may cause additional side effects or even life-threatening reactions when 
combined with the drugs being used in this study. If you experience side effects, changes in your health 
and/or changes in medications, please contact your study doctor or a study team member. 
You will have the following tests, procedures, and assessments done at the time points below: 
Cycle 1 
Cycle 2 and 
later 
(28 days) 
Day 1 Day 8 Day 15 Day 29 
Day 1 
Day 15 
Office Visit 
X 
X 
X 
Treatment 
Abemaciclib 
X1--------------------------------------------------------------X1 
Nivolumab 
X 
X 
Tests and Observations 
Physical exam 
X 
X 
Vital signs 
X 
X 
X 
Weight 
X 
X 
Performance status 
X 
X 
X 
Blood sample collection for blood cell count testing 
(1 tsp) 
X 
X 
X 
X 
X 
X2 
Blood sample collection for blood chemistry testing 
(1 tsp) 
X 
X 
X 
X 
X 
X2 
Blood sample collection to test blood clotting (1 tsp) 
X 
Blood sample collection for thyroid function testing 
(1 tsp) 
X 
Tumor Marker (1 tsp) 
X 
X 
Blood sample collection for pregnancy testing 
(women of childbearing potential) (1 tsp) 
X 
X 
CT/MRI 
X3 
Blood sample for research testing (10 tsp) 
X 
X 
X 
Tumor biopsies for research testing 
X4 
1.
Abemaciclib will be administered by mouth twice per day every day of each treatment cycle
2.
These lab tests will be required on Cycle 2 Day 15 but will only be required on Day 1 of Cycle 3 and
later cycles if the testing is normal or near-normal
3.
CT/MRI scans will be done approximately at Cycle 3 Day 1, Cycle 5 Day 1, then every 8 weeks
4.
A tumor biopsy will be collected during cycle 1 between days 15 and 19 
End of Study Visit: 
You will be asked to come in again 30 days after you have finished study treatment with abemaciclib for a 
Review of your general health and to see whether anything new has happened to you since your last 
study visit, including any side effects you may be experiencing.   
Post-Study Procedures: 
After your last study visit we will look into your medical records approximately every 6 months to gather 
information related to your overall health and any additional cancer treatments/procedures you may have 
undergone.   
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
5 of 19 
 
What are the possible risks or discomforts? 
While on the study, you are at risk for the following side effects. Some of these side effects may be 
potentially serious or life-threatening, and may include death. You should discuss these with the study 
doctor. There also may be other side effects that are not known and other very rare side effects that are 
known but not included in this list. If you experience side effects from the study drug(s), your study doctor 
may delay or skip a dose of the study drug, or ask you to stop taking study drug. Your doctors may also 
give you other drugs to help lessen these side effects. Many side effects go away shortly after the study 
drug is stopped, but in some cases side effects can be serious, long lasting or permanent.  
As there is little experience using nivolumab in combination with abemaciclib (the study drug), it is not yet 
clear how they will work together. This means that it is possible that the study drug may change how well 
the routine care drugs work in treating your disease (i.e. may make it more or less effective). 
Possible risks or discomforts with abemaciclib: 
Abemaciclib may cause one or more of the side effects listed below.  This information is based on data 
from cancer subjects in other clinical trials with abemaciclib.  In addition, there may be side effects that are 
not yet known that may occur.  You should tell your doctor or nurse right away about any possible side 
effects you experience. 
•
Gastrointestinal (GI) tract (stomach and intestines):
o
Diarrhea (90%)
o
Nausea (64%)
o
Decreased appetite (45%)
o
Abdominal pain (39%)
o
Vomiting (35%)
o
Constipation (17%)
o
Dry mouth (14%)
o
Mouth pain or sores (14%)
o
Weight loss (14%)
o
Abnormal taste (12%)
•
Bone marrow (which produces blood cells):
o
Low red blood cell count (anemia) (25%)
o
Low platelet count with increased risk of bleeding (20%)
o
Low neutrophil or white blood count with increased risk of infection (37%)
•
Kidney:
o
Worsened kidney function (13%)
o
Dehydration (10%)
•
Lungs and Respiratory System
o
Cough (19%)
•
Muscle and Bone
o
Joint pain (15%)
•
Nervous System
o
Headache (20%)
o
Dizziness (11%)
•
Fatigue (65%)
•
Infection (31%)
•
Hair loss (12%)
•
Fever (11%)
 Liver problems 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
6 of 19 
 
 Abemaciclib can cause serious liver problems. Your healthcare provider should do blood tests to check 
your liver before and during treatment with Abemaciclib. If you develop liver problems during treatment 
with Abemaciclib, your healthcare provider may reduce your dose or stop your treatment. Tell your 
healthcare provider right away if you have any of the following signs and symptoms of liver problems: 
O feeling very tired
o pain on the upper right side of your stomach area (abdomen)
o loss of appetite
o bleeding or bruising more easily than normal
Blood clots in your veins, or in the arteries of your lungs.  
Abemaciclib may cause serious blood clots that have led to death. Tell your healthcare provider right away 
if you get any of the following signs and symptoms of a blood clot: 
o pain or swelling in your arms or legs
o shortness of breath
o chest pain
Possible risks or discomforts with Nivolumab: 
Nivolumab may cause one or more of the side effects listed below.  This information is based on data from 
cancer subjects in other clinical trials with nivolumab.  In addition, there may be side effects that are not 
yet known that may occur.  You should tell your doctor or nurse right away about any possible side effects 
you experience.Very  common side effects of Nivolumab are: [greater than or equal to 10%] 
•
Fatigue
•
Itching
•
Rash
•
Diarrhea
Common side effects of Nivolumab are: [ greater than or equal to 1% and less than 10%] 
•
Abdominal pain
•
Alkaline phosphatase increased: lab test result associated with liver or bone abnormalities
•
Allergic reaction/hypersensitivity
•
ALT increased: lab test result associated with abnormal liver function
•
Amylase increased: lab test result associated with pancreas inflammation
•
AST increased: lab test result associated with abnormal liver function
•
Bilirubin (liver function blood test) increased
•
Chills
•
Constipation
•
Cough
•
Creatinine increased: lab test result associated with decreased kidney function
•
Decreased appetite
•
Dizziness or vertigo (feeling off balance which can lead to dizziness)
•
Dry mouth
•
Dry skin
•
Fever
•
Headache
•
Increased blood sugar
•
Inflammation of the colon
•
Inflammation of the mouth
•
Infusion related reaction
•
Lipase increased: lab test result associated with pancreas inflammation
•
Loss of color (pigment) from areas of skin
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC                                              UPCC 35218 (Penn IRB # 832174) 
 
Version:9/18/2019 
  
7 of 19 
 
• 
Lung inflammation (pneumonitis - see details below) 
• 
Musculoskeletal pain 
• 
Nausea 
• 
Redness (of the skin)  
• 
Shortness of breath 
• 
Sodium levels in the blood low  
• 
Swelling, including face, arms, and legs 
• 
Thyroid gland function decreased/ thyroid stimulating hormone increased: lab test result associated 
with abnormal thyroid function 
• 
Thyroid gland function increased 
• 
Tingling, burning, numbness or weakness, possibly in arms, legs, hands and feet 
• 
Vomiting 
 
 
Uncommon side effects of Nivolumab include:[Less than 1%] 
• 
Adrenal gland function decreased 
• 
Bronchitis 
• 
Dehydration 
• 
Diabetes 
• 
Double Vision 
• 
Dry Eye 
• 
Erythema multiforme (A skin disorder characterized by bullseye-shaped lesions) 
• 
Hair loss 
• 
Heart rate increased 
• 
Heart rythym abnormal 
• 
High blood pressure 
• 
Hives 
• 
Inflammation of the eye 
• 
Inflammation of the kidney 
• 
Inflammation of the pancreas 
• 
Inflammation of the pituitary gland 
• 
Inflammation of the stomach 
• 
Inflammation of the thyroid gland 
• 
Joint pain or stiffness 
• 
Liver inflammation 
• 
Low blood pressure 
• 
Muscle inflammation 
• 
Pemphigoid: blistering of the skin or mouth caused by the immune system attacking healthy tissue. 
• 
Pituitary gland function decreased 
• 
Psoriasis: characterized by patches of abnormal, scaly skin 
• 
Renal (kidney) failure or kidney injury 
• 
Respiratory failure 
• 
Upper respiratory tract infection 
• 
Vision blurred 
• 
Weight loss 
• 
Blood chemistry abnormalities, including low blood phosphate, magnesium, and potassium levels. 
• 
High blood uric acid level 
• 
Abnormal taste  
• 
Increased sensitivity of skin to sunlight 
• 
Difficulty swallowing 
• 
Heartburn 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC                                              UPCC 35218 (Penn IRB # 832174) 
 
Version:9/18/2019 
  
8 of 19 
 
 
Rare but potentially serious side effects of Nivolumab include: [less than 0.1%] 
• 
 Lung infiltrates, associated with infection or inflammation 
• 
Anaphylactic reaction (severe allergic reaction) 
• 
Cranial nerve disorder 
• 
Damage to the protective covering of the nerves in the brain and spinal cord 
• 
Diabetes complications resulting in excess blood acidsGuillain-Barre syndrome, an autoimmune 
disorder associated with progressive muscle weakness or paralysis  
• 
Sarcoidosis, a disease involving abnormal collections of inflammatory cells (granulomas) in organs 
such as lungs, skin, and lymph nodesDrug induced liver injuryAbnormal blood cell production 
• 
Inflammation of blood vessels 
• 
Sores in the mouth which may cause difficulty swallowing  
• 
Back pain 
• 
Autoimmune disorders, including Guillain-Barre syndrome (associated with progressive muscle 
weakness or paralysis)  
• 
Chest discomfort 
• 
Heart palpitations 
• 
Inflammation of the heart  (may be life threatening or fatal) 
• 
Collection of fluid around the heart 
• 
Infections: including sepsis, lung infections, and skin infections.  
• 
Decreased movement of the intestines 
• 
Disorientation 
• 
Inflammationof the lining of the brain and spinal cord 
• 
Inflammation of the brain, potentially life threatening or fatal 
• 
Lung infiltrates, associated with infection or inflammation 
• 
Polymyalgia rheumatic (muscle pain and stiffness around the shoulders and hips) 
• 
Disease caused by the body’s immune system attacking healthy organs  
• 
Drug induced liver injury 
• 
Stevens Johnson syndrome: inflammatory disorder of skin and mucous membranes, resulting in 
blistering and shedding of skin 
• 
Syndrome associated with fever, white blood cell activation and abnormal function (including 
destruction of other blood cells by certain white blood cells), low blood cell counts, rash, and 
enlargement of the spleen 
• 
Histiocytic necrotizing lymphadenitis or Kikuchi lymphadenitis: disorder of the lymph nodes which 
causes the lymph nodes to become enlarged, inflamed and painful, commonly affecting lymph 
nodes of the neck and possibly associated with fever or muscle and joint pains.  
• 
Rosacea: acne-like skin condition resulting in redness of face 
• 
Rupture of the intestine/hole in the intestine 
• 
Drug reaction with rash, blood cell abnormalities, enlarged lymph nodes, and internal organ 
involvement (including liver, kidney, and lung); known as Drug Reaction with Eosinophilia and 
Systemic Symptoms (DRESS) 
• 
Myasthenia gravis, a nerve disease that may cause weakness of eye, face, breathing, and 
swallowing muscles. One death in a patient who received Nivolumab combined with Ipilimumab 
was considered due to myasthenia gravis and severe infection (sepsis). 
• 
 Toxic epidermal necrolysis, a potentially fatal disease characterized by blistering and peeling of 
the top layer of skin resembling a severe burn, has occurred in patients who received Nivolumab 
treatment. 
• 
Rhabdomyolysis (muscle fiber released into the blood stream which could damage your kidney) 
and polymyositis (chronic muscle inflammation with muscle weakness) has been reported in one 
patient. 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC                                              UPCC 35218 (Penn IRB # 832174) 
 
Version:9/18/2019 
  
9 of 19 
 
• 
Vogt Koyanagi Harada syndrome; a disease that affects the pigmented tissue; this may affect the 
eye leading to swelling,  pain and/or  blurred vision;  the ear leading to hearing  loss , ringing in the 
ears and /or the skin leading to loss of skin color 
 
o 
Lung Inflammation (Interstitial Lung Disease/ Pneumonitis):  It is possible that Nivolumab and 
Abemaciclib may cause inflammation of the tissues of the lung.  This adverse effect has been 
reported infrequently in patients treated with Nivolumab.  While many patients with x-ray or CT 
abnormalities have not developed any symptoms, some patients have developed mild to severe 
symptoms and in rare cases, death has occurred as a result of their lung inflammation.  Signs and 
symptoms of lung inflammation may include difficulty breathing, pain or discomfort while breathing, 
chest pain, cough (with or without mucus), shortness of breath (while at rest or with low activity), 
increased rate of breathing, fever, low blood oxygen levels, or fatigue. Abemaciclib may also cause 
lung tissue scarring. 
   
Your study doctor and nurse will watch you closely for changes in your ability to breathe and for other 
signs or symptoms that might show you are developing this type of lung inflammation and will perform 
regular tests including physical exams, measurement of oxygen levels through non-invasive testing (i.e., 
pulse oximeter), blood tests, chest x-rays and/or CT scans. 
 
 
Please inform your study doctor or nurse AT ONCE if you experience any of the following: 
• 
Any new or increased shortness of breath; 
• 
Any new or increased chest pain; 
• 
Any new or increased pain/difficulty while breathing; 
• 
Any new or increased cough or any significant change in your type of cough; for example, any new 
or increased mucous or blood in your cough;   
• 
Any change in the amount of oxygen you require; 
• 
Any fever, fatigue, or other symptoms that occur at the same time as any changes to your 
breathing or other lung symptoms.  
 
If you start to develop symptoms, your study doctor will ask you to return to the clinic for additional tests, 
which could include a physical exam, measurement of oxygen levels, blood tests, chest x-rays, and/or CT 
scans. You will be monitored very closely for changes in your overall lung symptoms, monitoring may 
require hospitalization. You may require specific treatment in order to control pneumonitis. You may also 
be seen by a special doctor called a pulmonologist, who has special training to be an expert in how your 
lungs work. 
 
Prolonged treatment with medicines that suppress inflammation, sometimes needed to manage the side 
effects of Nivolumab treatment, may lower your body’s ability to fight off certain infections (i.e., 
opportunistic infections). These infections may require treatment with antibiotic or antifungal medications 
and may be fatal. 
 
Other Study Related Risks 
Risks of Blood Draws 
Blood samples will be taken for tests throughout this study. The amount of blood to be taken by these 
blood draws is very small, and may be associated with discomfort and/or bruising at the site where the 
needle is inserted; and less commonly, fainting, the formation of a small blood clot or swelling of the vein 
and surrounding tissue, bleeding, and infection from the injection site. The total volume to be collected will 
depend upon the number of treatment visits and the duration of safety follow-up. 
 
 
 
 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
10 of 19 
 
Risk of IV  
An IV line will be used to administer study drug through a vein in your arm. The use of an IV line may 
cause discomfort, irritation, mild bruising, bleeding, leakage of drug solution, and rarely infection, nausea, 
and lightheadedness. 
Risks of Infusion-Related Reaction 
Infusions of drugs can cause allergic reactions in people.  Allergic reactions may include shortness of 
breath, itching, rash, low blood pressure, and fever during the infusion or shortly after.  If you experience 
any of these symptoms, you should contact your doctor immediately.  Sometimes these reactions can be 
serious and can result in death if not watched carefully.  You will be watched by medical personnel for 
signs of allergic reactions, and you will be given medicine if you need it.  
Risks of Imaging Tests 
During your participation in this study, you may undergo routine radiology tests to assess your disease. 
These can include CT, x-rays and MRI scans. Each of these procedures has risks associated with it, and 
you should talk to your study doctor or the person doing these procedures about the risks before they 
start. 
•
Radiation Exposure: This research study involves exposure to radiation from the X-rays and CT.
Therefore, you will receive a radiation dose. Some of these procedures may not be necessary for
your medical care and will occur only as a result of your participation in the study. At exposure
levels much higher than you will receive, radiation is known to increase the risk of developing
cancer after many years. At the exposure level you will receive, it is very likely that you will see no
effects at all.
•
CT Scans: A CT scan is an imaging method that uses x-rays to create cross-sectional pictures of
the body. You will be asked to lie on a narrow table that slides into the center of the CT scanner.
Depending on the study being done, you may need to lie on your stomach, back, or side. Once you
are inside the scanner, the machine's x-ray beam rotates around you. It is important to remain still
during the exam, because movement causes blurred images. You may be told to hold your breath
for short periods of time. The scans take about 15 minutes or less to complete.
o
It is important to inform your study doctor if you have had an allergic reaction to IV contrast
material in the past, or if you have an allergy to iodine. Most CT contrast reactions
(approximately 95%) are mild to moderate in degree and most resolve themselves without
treatment. However, life-threatening reactions and fatalities, mostly of cardiovascular origin,
have occurred. People with heart disease, kidney disease or allergies are more likely to
have a more severe reaction to contrast agents. If you have a history of kidney disease,
allergies or heart disease, please inform the study staff. Likely contrast reactions include
feelings of overall warmth (especially in the bladder area after injection), a metallic taste
during the injection, and warmth, burning sensation, or momentary pain during the contrast
injection at the injection site. Less likely contrast reactions include nausea, vomiting,
headache, hives, and itching. Rare but serious contrast reactions include faster than normal
heart rate (tachycardia), high blood pressure (hypertension), low blood pressure
(hypotension), heart attack, kidney failure, fluid in the lungs (pulmonary edema), serious
allergic reaction, and death. There is also a risk that multiple needle sticks will be necessary
to ensure proper intravenous line placement. There may be a small amount of pain or
bruising with the placement of the intravenous catheter (IV) and a small risk of infection at
the injection site.
•
MRI: The known risks associated with a Magnetic Resonance Imaging (MRI) are minimal. The
procedure uses radio waves and a magnetic field to take pictures. The greatest risk of having an
MRI is the chance of metal objects flying through the air toward the magnet and hitting you. To
reduce this risk, all people involved with the study are instructed to remove all metal from their
clothing and all metal objects from their pocket. You must tell your study doctor if you have any
metal plates or clips in your body. No metal objects are allowed to be brought into the magnet room
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
11 of 19 
 
at any time. Metal objects inside your body can affect the test results and could lead to injury. 
Because the magnetic field of the MRI scanner attracts metal, these studies will not be performed 
on anyone with a pacemaker or any non-removable metallic foreign objects in their body. If you 
have any such object on your body, you will not receive the scan. You may feel claustrophobic 
(fear of being closed in) or anxious. You may experience some discomfort and fatigue from lying in 
a confined space. There are no known effects from exposure to the magnetic fields. 
Risks of a Biopsy 
A biopsy is an invasive test in which your cells and/or tissue are collected for examination. It involves the 
surgical removal of a small bit of tissue for examination. Your study doctor will explain this procedure to 
you in more detail, and you will be given a standard hospital consent form to sign detailing your specific 
type of biopsy prior to the procedure. 
Risks of a biopsy include, but are not limited to: 
Likely risks: 
•
Pain
•
Discomfort
•
Soreness
•
Minor bleeding
•
Bruising
Less likely risks: 
•
Redness
•
Swelling
•
Bleeding
•
Lung collapse (pneumothorax) - air which leaks out of the lung and collects between the lung and the
ribs, sometimes causing shortness of breath and chest pain, and which may require hospitalization
admission and chest tube placement for the evacuation (release) of air
Rare risks: 
•
Bleeding, life threatening hemorrhage
o
Hemorrhage - bleeding around the lesion
o
Hemothorax - bleeding around the lung
•
Possible damage to adjacent organs
•
Drainage from the biopsy site
•
Abnormal wound healing
•
Fever
•
Infection
•
Allergic reaction to the medication used to numb the skin over the biopsy site
Rarely, these complications can lead to the need for intubation (placement of a breathing tube) or surgery. 
A very rare complication of lung biopsy is air embolism, defined as air that enters the blood stream, which 
can be life-threatening. 
As with any invasive procedure and the use of sedation, additional risks include, but are not limited to: 
bleeding related to needle placement; injury to nearby organs, vessels and nerves; and breathing 
difficulties. In addition to these potential complications, there may be other unpredictable complications, 
including death. 
It is also possible that the procedure may yield inconclusive results (“non-diagnostic”) due to sampling 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
12 of 19 
 
limitations (not enough tissue to sample) or to limitations in being able to interpret the results of the sample 
in the laboratory. 
Risks of Genetic Research  
The research testing done as a part of this study includes genetic testing. Even without your name or other 
identifiers, your genetic information is unique to you. The researchers believe the chance that someone 
will identify you is very small, but the risk may change in the future as people come up with new ways of 
tracing information.  
There can be a risk in knowing genetic information. New health information about inherited traits that might 
affect you or your blood relatives could be found during a research study. Even though your genes are 
unique, you share some of the same genes with your blood relatives. Although we are not able to know all 
of the risks from taking part in research on inherited traits, we believe that the risks to you and your family 
are very low, because your samples will be coded. Research results will not be returned to you or your 
doctor.  
Very rarely health or genetic information could be misused by employers, insurance companies, and 
others. For example, it could make it harder for you to get or keep a job or insurance, or life insurance 
companies may charge a higher rate based on this information. We believe the chance these things will 
happen is very small, but we cannot make guarantees.  
A federal law (Genetic Information Non-Discrimination Act, GINA) helps reduce the risk from health 
insurance or employment discrimination. The law does not include other types of misuse by life insurance 
or long term care insurance. If you want to learn more about GINA, you can find information about it on the 
internet or ask the study staff. 
Reproductive Risks 
Female Participants 
You should not become pregnant while you or your sexual partner are taking Nivolumab and for 6 months 
after your last dose of study drug because the study drugs could have a negative effect on an unborn 
baby. In this case, we do not have enough information about Nivolumab to determine if it could cause 
problems for a pregnancy or developing baby. In addition, you should not breastfeed while on this study as 
these drugs may also affect a breast-feeding child.  Pregnant women and women who are breast-feeding 
are not allowed to participate in this study. If you become pregnant, you will no longer be able to 
participate in this study. 
If you are able to have children, you must agree to use a medically accepted form of birth control including 
condoms, diaphragms, cervical cap, an intra-uterine device (IUD), surgical sterility (tubal ligation or a 
partner that has undergone a vasectomy), or oral contraceptives, OR you must agree to completely 
abstain from intercourse during participation in this study and for 3 weeks after your last dose of study 
drug.  Abstinence at certain times of the cycle only, such as during the days of ovulation, after ovulation 
and withdrawal are not acceptable methods of birth control.  Ask your study doctor about the contraceptive 
methods that are available and which might be the best for you.   
Even when you use an approved contraceptive method, there is always a small risk that you could still 
become pregnant. If you do become pregnant during the course of this study or up to 3 weeks after your 
last dose of study drug, you must discontinue study treatment, tell the investigator immediately, and 
consult an obstetrician or maternal-fetal specialist. If you become pregnant while on this study, we will ask 
permission to collect information about your pregnancy. 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC                                              UPCC 35218 (Penn IRB # 832174) 
 
Version:9/18/2019 
  
13 of 19 
 
If you become pregnant during this study, suspect pregnancy or if you missed your period or it is late, 
or if you have a change in your usual menstrual cycle (e.g., heavier bleeding during your period or 
bleeding between periods), you should immediately contact your study doctor.  
 
1. You will discontinue nivolumab immediately. When study drug is permanently discontinued, you 
may be instructed about continued use of other medications. 
2. The study doctor will help you understand how nivolumab might affect your pregnancy. This will 
be based on all the information available at that time. 
3. You will be referred to other doctors for pre-natal medical care. Your study doctor will be 
available to counsel other doctors about how nivolumab might affect your pregnancy. 
4. The study doctor will ask for your permission to follow the progress of your pregnancy, provided 
it is safe for you and your unborn baby to do so. This information will be used to advise other 
women who might become pregnant while taking the study medication. 
 
In case of a pregnancy, your pregnancy and its outcome will be reported to the study sponsor. Your 
doctor will discuss this with you, as well as options for additional appropriate care for your cancer.  
 
The sponsor has not set aside any funds to pay for any aspects of obstetric, child or related care and 
does not plan to pay for them. 
 
 
What if new information becomes available about the study? 
During the course of this study, we may find more information that could be important to you (such as new 
information about how the drug works or newly discovered side effects). If we discover new information 
about the study that could affect your decision to stay in the study, you will be notified in a timely manner. 
You will be able to ask questions about this new information and can discuss it with your family, friends, or 
doctor.  
 
What are the possible benefits of the study?  
Taking part in this study may or may not make your health better. However, while you may not benefit 
personally, the knowledge learned from your participation in this research study may benefit other patients 
in the future. It is possible that your disease and/or health may worsen as a result of participating in this 
study. 
 
What other choices do I have if I do not participate?  
Your participation in this study is entirely voluntary.  Other possible options include: 
• 
Getting treatment or care for your cancer without being in a study. 
• 
Taking part in another study. 
• 
Not receiving treatment at this time. 
• 
Getting comfort care, also called palliative care. This type of care helps reduce pain, tiredness, appetite 
problems and other problems caused by the cancer. It does not treat the cancer directly, but instead 
tries to improve how you feel. Comfort care tries to keep you as active and comfortable as possible.   
 
Talk to your doctor about your choices before you decide if you will take part in this study.  
 
Will I be paid for being in this study? 
You will not be paid for taking part in this study. 
 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC                                              UPCC 35218 (Penn IRB # 832174) 
 
Version:9/18/2019 
  
14 of 19 
 
Will I have to pay for anything? 
Eli Lilly Corporation, the manufacturer of abemaciclib, is supplying abemaciclib for the purposes of this 
study at no cost to you. You and/or your insurance company will be responsible for the costs of nivolumab, 
including drug administration. 
 
You will be responsible for any deductibles or applicable co-pays for the standard tests, exams or 
procedures that would be done for your routine clinical care, such as office visits, scans and blood work. 
You and/or your insurance provider will be responsible for standard tests, exams or procedures that would 
be done even if you were not in this study.  Please talk to your doctor and study team about putting you in 
touch with a financial counselor to determine exactly what the deductible and co-pay will be for you; this is 
highly variable depending on your type of insurance. There will be no charge to you for those laboratory 
tests and other procedures that are being done specifically for the purposes of this research study.   
 
For more information on clinical trials and insurance coverage, you can visit the National Cancer Institute’s 
Website at: http://cancer.gov/clinicaltrials/understanding/insurance-coverage. You can print a copy of the 
“Clinical Trials and Insurance Coverage” information from this Website. 
 
Another way to get the information is to call 1-800-4-CANCER (1-800-422-6237) and ask them to send 
you a free copy. 
 
What happens if I am injured or hurt during the study? 
All side effects, injuries or illnesses that occur while you are taking part in this research study: 
If you have a medical emergency during your participation on this study, you should go to the nearest 
emergency room.  You should contact the Principal Investigator or Emergency contact listed on page one 
of this form. You may also contact your own doctor or seek treatment outside of the University of 
Pennsylvania.  Be sure to tell the doctor or his/her staff that you are in a research study being conducted 
at the University of Pennsylvania. Ask them to call the telephone numbers on the first page of this consent 
form for further instructions or information about your care. 
 
The University of Pennsylvania will offer you the care needed to treat side effects and/or injuries that occur 
while you are taking part in this research.  We may bill your insurance company or other third parties, if 
appropriate, for the costs of the care you get for the injury, but you may also be responsible for some of 
them.  There are no plans for the University of Pennsylvania or Eli Lilly Corporation to pay you or give you 
other compensation for the injury.   
 
You may receive bills for injuries/illnesses that occur during your participation in this study. If you have 
questions about these bills and whether or not they are covered by the research study, please bring 
copies of these bills to a member of the study team and they will be able to answer your questions. 
 
Financial compensation for such things as traveling, parking, lost wages, disability or discomfort due to 
injury is not routinely available.   
 
You will not lose any of your legal rights when you sign this form. 
 
When is the Study over?  Can I leave the Study before it ends? 
You may stop participating at any time. However, if you decide to stop participating in the study, we 
encourage you to talk to your doctor first. You can also choose to leave the study at any time without 
giving a reason. It is important to tell the doctor if you are thinking about stopping so any risks for the 
treatments that you received can be evaluated by your doctor. Another reason to tell your doctor that you 
are thinking about stopping is to discuss what follow-up care and testing could be most helpful for you. 
Leaving the study will not affect your future medical care. 
 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
15 of 19 
 
The doctor may stop you from taking part in this study at any time if he/she believes that it is in your best 
interest, if you do not follow the study rules, or if the study is stopped. If new information becomes 
available that might affect your choice to stay in the study, your study doctor will notify you as soon as 
possible. 
This study may also be stopped at any time by your study doctor, the study Sponsor, or the Food and 
Drug Administration (FDA) without your consent because: 
•
The Principal Investigator or the sponsor feels that it is in your best interest to discontinue the
study.  Such an action would not require your consent, but you will be informed if such a
decision is made and the reason for this decision.
•
You have not followed study instructions, or you become pregnant
•
The Sponsor, the study Principal Investigator, or the Food and Drug Administration (FDA) has
decided to stop the study due to new information regarding side effects.
•
It is determined that you are no longer benefiting from the study therapy
•
For any other reason that is not known at this time
If you are removed from the research study, your study doctor will explain to you why you were removed. 
The study doctor and study team will help arrange for your continued care. 
Who can see or use my information?  How will my personal information be 
protected?   
If you decide to participate in this study, the study doctor and staff will collect medical and personal 
information about you as part of completing the study. We will do our best to make sure that the personal 
information in your medical record will be kept private. However, we cannot guarantee total privacy. Your 
personal information may be given out if required by law. If information from this study is published or 
presented at scientific meetings, your name and other personal information will not be used. This study is 
being overseen by the Food and Drug Administration (FDA); therefore they may review your research 
records. Please refer to the information below which explains more specifically how your personal 
information will be protected. If you do not want to allow these uses, you should not participate in this 
study. Information identifying you will be kept confidential as described below. 
What personal health information is collected and used in this study, and might also be disclosed? 
The following personal health information will be collected and used for the purposes of this study. 
•
Name, address, telephone number,
gender, date of birth
•
The history and diagnosis of your
disease
•
Specific information about the therapy
you received, including previous
treatment(s) you may have had
•
Information about other medical
conditions that may affect your care
•
Medical data including laboratory test
results, health status, x-rays, CTs, MRIs,
pathology results, etc.
•
Information on side effects (adverse
events) you may experience, and how
these were treated
•
Long-term information about your general
health status and the status of your
disease. This may include information
from other health care providers.
•
Data that may be related to tissue
samples that may be collected from you
•
Numbers or codes that will identify you,
such as your medical record number
•
Information related to study visits and
other tests/procedures performed while
you are participating on this study.
While collected as part of this study by your study doctor and study team, identifying information (including 
your name, address, telephone number, medical record number, or any number/codes that will directly 
identify you) will be kept as confidential as possible and will not be routinely disclosed outside of the 
University of Pennsylvania. Personal health information that could be used to identify you will not be sent 
to Eli Lilly Corporation, and/or their designated representatives.   
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC                                              UPCC 35218 (Penn IRB # 832174) 
 
Version:9/18/2019 
  
16 of 19 
 
 
You will be assigned a unique subject registration number upon enrollment. This number and your initials 
will be used to identify you throughout the course of this study so that your identity is protected. The key to 
this code (which links your name back to the personal health information collected during this study) will 
be stored in a secure area and only the University of Pennsylvania study team will have access to this 
code. However, some of the study data (e.g. date of birth) could be used in combination with other 
information, in order to identify you. If you have questions about the specific information that will be 
released, you should ask your study doctor.  
 
Why is my personal health information being used? 
Your personal contact information is important for the research team to contact you during the study. Your 
personal health information and results of tests and procedures are being collected as part of this research 
study, and will be used to conduct and oversee this research study, and to help guide your medical care.    
 
Which personnel may use or disclose my personal health information? 
The following individuals may use or disclose your personal health information for this research study: 
• 
The Principal Investigator and the Investigator’s study team  
• 
Authorized members of the workforce of the UPHS and the School of Medicine, and University of 
Pennsylvania support offices, who may need to access your information in the performance of their 
duties (for example: for research oversight and monitoring, to provide care as part of this study or as 
part of your routine care, to manage accounting or billing matters, etc.).  This includes members of 
the Institutional Review Board (IRB), an Ethics Committee at the University of Pennsylvania who are 
responsible for reviewing and overseeing research studies to ensure that they are safe and being 
well managed.  
• 
Other research personnel with access to the databases for research and/or study coordination and 
as otherwise approved by the IRB 
 
Who, outside of UPHS and the School of Medicine, might receive my personal health information?  
As part of the study, the Principal Investigator, the study team and others listed above, may disclose your 
study-related records, including the results of the research study tests and procedures, to those listed 
below. This study data may be processed and transmitted using secure computer systems. In all 
disclosures outside of the University of Pennsylvania Health System and School of Medicine, you will not 
be identified by name, medical record number, address, telephone number, or any other direct personal 
identifier unless disclosure of the direct identifier is required by law. In records and information disclosed 
outside of the University of Pennsylvania Health System and School of Medicine, you will be assigned a 
unique code number.  
 
Your original medical records also may be reviewed by the sponsor of this study or its designated 
representatives, the Institutional Review Board overseeing this study, and any of the regulatory or safety 
oversight organizations outlined below. They may review these records for the purpose of checking data 
collected for the study, to make sure the study is being done properly, and to analyze the results of the 
study.  
 
Individuals or organizations responsible for administering the study:  
• The Principal Investigator and the Investigator’s study team 
• Eli Lilly Corporation (who may receive serious side effect information) 
 
Regulatory and safety oversight organizations 
• 
The U.S. Food and Drug Administration (FDA) 
• 
Other regulatory agencies and/or their designated representatives, including international agencies 
• 
Public Health agencies and other government agencies (including non-U.S.) as authorized or 
required by law 
 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
17 of 19 
 
Once your personal health information is disclosed to others outside of UPHS or the School of Medicine, it 
may no longer be covered by United States federal privacy protection regulations.  
The Principal Investigator or study staff will inform you if there are any additions to the list above during 
your active participation in the trial. Any additions will be subject to University of Pennsylvania procedures 
developed to protect your privacy. 
How long may UPHS and the School of Medicine be able to use or disclose my personal health 
information?   
Your authorization for use of your personal health information for this specific study does not expire. If you 
sign this form, we will collect your health information until the end of the research study. We may collect 
some information from your medical records even after you finish taking part in this study or after your 
death. We will keep all of the information forever in case we need to look at it again. We will protect this 
information and keep it confidential. 
Your information may be held in a research database. However, UPHS and the School of Medicine may 
not re-use or re-disclose information collected in this study for a purpose other than this study unless: 
•
You have given written authorization to do so
•
The University of Pennsylvania’s Institutional Review Board grants permission after ensuring that
appropriate privacy safeguards are in place
•
As permitted by law
The data from this study may be published or used for teaching purposes, however you will not be 
personally identified in any publication. Your identity will remain confidential unless disclosure is required 
by law. 
What if I decide not to give permission to use and give out my health information? 
Then you will not be able to be in this research study. 
Can I change my mind? 
You have the right to withdraw your permission for the use of your personal health information, but if you 
do so, you must stop taking part in this study. You must do so in writing to the Principal Investigator at the 
address on the first page. Even if you withdraw your permission, your personal health information that was 
collected before we received your written request may still be used and disclosed, as necessary for the 
study. If you withdraw your permission to use your personal health information, you will also be withdrawn 
from the research study and no new information will be collected. However, even if you do withdraw your 
permission to use the data about you, we are required by the FDA and other national regulatory authorities 
to record anything that relates to the safety of the investigational drug under study. 
Will I be able to access my research records? 
You have the right to see and get a copy of your medical records kept by the University of Pennsylvania. 
However, you will not be able to review or receive some of your records related to the study until after the 
entire study has been completed. When the study is over, you may write to the study doctor to ask to see 
or copy all of your medical information that was collected during the study. You also have the right to say 
how your medical information may be used, and to have any incorrect data about yourself updated or 
corrected.   
A description of this clinical trial will be available on http://www.clinicaltrials.gov, as required by US Law. 
This website will not include information that can identify you. At most, the website will include a summary 
of the results. You can search this website at any time. 
By signing this document, you are permitting the UPHS and the School of Medicine to use and disclose 
personal health information collected about you for research purposes as described above. 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC                                              UPCC 35218 (Penn IRB # 832174) 
 
Version:9/18/2019 
  
18 of 19 
 
 
What is an electronic medical record and/or a clinical trial management 
system?  
An Electronic Medical Record (EMR) is an electronic version of the record of your care within a health 
system. An EMR is simply a computerized version of a paper medical record.  
A clinical trial management system (CTMS) is used to register your information as a participant in a study 
and to allow for your research data to be entered/stored for the purposes of data analysis and any other 
required activity for the purpose of the conduct of the research.  
 
If you are receiving care or have received care within the University of Pennsylvania Health System 
(UPHS) (outpatient or inpatient) and are participating in a University of Pennsylvania research study, 
information related to your participation in the research (i.e. laboratory tests, imaging studies and clinical 
procedures) may be placed in your existing EMR maintained by UPHS. Information related to your 
participation in clinical research will also be contained in the CTMS. 
 
If you have never received care within UPHS and are participating in a University of Pennsylvania 
research study that uses UPHS services, an EMR will be created for you for the purpose of maintaining 
any information produced from your participation in this research study.  The creation of this EMR is 
required for your participation in this study. In order to create your EMR, the study team will need to obtain 
basic information about you that would be similar to the information you would provide the first time you 
visit a hospital or medical facility (i.e. your name, the name of your primary doctor, the type of insurance 
you have). Information related to your participation in the study (i.e. laboratory tests, imaging studies and 
clinical procedures) may be placed in this EMR.  
 
Once placed in your EMR or in the CTMS, your information may be accessible to appropriate UPHS 
workforce members that are not part of the research team.  Information within your EMR may also be 
shared with others who are determined by UPHS to be appropriate to have access to your EMR (e.g. 
health insurance company, disability provider, etc.).  
 
Who can I call with questions, complaints or if I’m concerned about my rights 
as a research subject? 
If you have questions, concerns or complaints regarding your participation in this research study you 
should speak with the Principal Investigator listed on page one of this form.  If you have any questions 
about your rights as a research subject, you may contact the Office of Regulatory Affairs at the University 
of Pennsylvania with any questions, concerns or complaints by calling (215) 898-2614. 
 
Where can I get more information? 
You may call the National Cancer Institute’s Cancer Information Service at 1-800-4-CANCER (1-800-422-
6237).  You may also visit the NCI website at http://cancer.gov/. For NCI’s clinical trials information, go to 
http://cancer.gov/clinicaltrials/. 
For 
NCI’s 
general 
information 
about 
cancer, 
go 
to 
http://cancer.gov/cancerinfo. 
 
IRB Approved 12/14/2019 to 11/05/2020

Abemaciclib and Nivolumab for HCC 
 UPCC 35218 (Penn IRB # 832174) 
Version:9/18/2019 
19 of 19 
 
When you sign this form, you are agreeing to take part in this research study. This means that you have 
read the consent form, the study has been explained to you, your questions have been answered, you 
have had time to make your decision, and you have decided to volunteer to participate. You have been 
given the names of study staff that you can contact if you need assistance or if you have any additional 
questions or concerns. You agree to follow all of the instructions of your study doctor to the best of your 
ability, and report any changes in your health that may occur during the study. 
Your signature also means that you are permitting the University of Pennsylvania Health System and the 
School of Medicine to use your personal health information collected about you for research purposes 
within our institution. You are also allowing the University of Pennsylvania Health System and the School 
of Medicine to disclose that personal health information to outside organizations or people involved with 
the operations of this study.   
You agree that your primary care physician can be informed about your participation in this clinical trial. 
A copy of this signed and dated consent form will be given to you. 
_________________________________ 
___________________________     _____________ 
Name of Subject (Print) 
Signature of Subject  
    Date 
_________________________________ 
___________________________      _____________ 
Name of Person Obtaining 
Signature of Person Obtaining 
    Date 
Authorization (Print) 
Authorization 
IRB Approved 12/14/2019 to 11/05/2020